



2014-06-02

Studies on the Synthesis of Orthogonally Protected Azalanthionines, and of Routes towards β -Methyl Azalanthionines, by Ring-Opening of N-Activated Aziridine-2-Crboxylates

Keith O'Brien

Institute of Technology, Tallaght


Keith Ó Proinsias

Institute of Technology, Tallaght

Fintan Kelleher

Institute of Technology, Tallaght, fintan.kelleher@ittdublin.ie

Follow this and additional works at: <http://arrow.dit.ie/ittsciart>

 Part of the [Medicinal-Pharmaceutical Chemistry Commons](#), and the [Organic Chemistry Commons](#)

Recommended Citation

O'Brien, Keith; Ó Proinsias, Keith; and Kelleher, Fintan, "Studies on the Synthesis of Orthogonally Protected Azalanthionines, and of Routes towards β -Methyl Azalanthionines, by Ring-Opening of N-Activated Aziridine-2-Crboxylates" (2014). *Articles*. 32.
<http://arrow.dit.ie/ittsciart/32>

This Article is brought to you for free and open access by the School of Science and Computing at ARROW@DIT. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@DIT. For more information, please contact yvonne.desmond@dit.ie, arrow.admin@dit.ie, brian.widdis@dit.ie.



Accepted Manuscript

Studies on the synthesis of orthogonally protected azalanthionines, and of routes towards β -methyl azalanthionines, by ring-opening of N-activated aziridine-2-carboxylates

Keith O'Brien , Keith ó Proinsias , Fintan Kelleher



PII: S0040-4020(14)00857-6

DOI: [10.1016/j.tet.2014.06.011](https://doi.org/10.1016/j.tet.2014.06.011)

Reference: TET 25676

To appear in: *Tetrahedron*

Received Date: 20 January 2014

Revised Date: 19 May 2014

Accepted Date: 2 June 2014

Please cite this article as: O'Brien K, ó Proinsias K, Kelleher F, Studies on the synthesis of orthogonally protected azalanthionines, and of routes towards β -methyl azalanthionines, by ring-opening of N-activated aziridine-2-carboxylates, *Tetrahedron* (2014), doi: 10.1016/j.tet.2014.06.011.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Studies on the synthesis of orthogonally protected azalanthionines, and of routes towards β -methyl azalanthionines, by ring-opening of N-activated aziridine-2-carboxylates

Keith O'Brien, Keith ó Proinsias and Fintan Kelleher*

*Molecular Design and Synthesis Group, Centre of Applied Science for Health,
Institute of Technology Tallaght, Dublin 24, Ireland.*

Corresponding Author: Dr. Fintan Kelleher

Address: Department of Science,
Institute of Technology Tallaght,
Tallaght,
Dublin 24,
Ireland.

Phone Number: (+353 1) 404 2869


Fax Number: (+353 1) 404 2700

e-mail address: fintan.kelleher@ittdublin.ie

Graphical abstract:

Studies on the synthesis of orthogonally protected azalanthionines, and of routes towards β -methyl azalanthionines, by ring-opening of N-activated aziridine-2-carboxylates

Keith O'Brien, Keith ó Proinsias and Fintan Kelleher*



Orthogonally protected Azalanthionine

Studies on the synthesis of orthogonally protected azalanthionines, and of routes towards β -methyl azalanthionines, by ring-opening of N-activated aziridine-2-carboxylates

Keith O'Brien, Keith ó Proinsias and Fintan Kelleher*

Molecular Design and Synthesis Group, Centre of Applied Science for Health, Institute of Technology Tallaght, Dublin 24, Ireland.

Abstract:

Orthogonally protected azalanthionines were successfully synthesised by the ring-opening of N-activated aziridine-2-carboxylates with protected diaminopropanoic acids (DAPs). The required DAPs were also prepared by ring-opening of N-activated aziridine-2-carboxylates with *para*-methoxybenzylamine, but it was found that the choice of aziridine protecting groups dictated both the success of the reaction as well as the regioselectivity of the isolated products. Attempts to extend the methodology to the preparation of the more sterically demanding β -methyl azalanthionines have, so far, been unsuccessful.

Keywords:

1,2-Diaminopropanoic acids (DAPs); Lanthionine; Aziridine-2-carboxylates; Ring-opening; Azalanthionines; β -Methyl azalanthionines.

1. Introduction

The incorporation of amino acid cross-linkers into peptide structures, which leads to the formation of cyclic peptides, is an important way that nature uses to give defined peptide and protein conformations with high biological activity. Importantly the stability of the peptides can also be increased due to their increased resistance to proteolytic cleavage.¹ There are many such cross-linkers in nature including lysinoalanine and histidinoalanine,² while the lanthipeptides contain the lanthionine or β -methylanthionine cross-linking amino acids (Figure 1).³ Nisin is one of the most studied lanthipeptides and is a highly active antimicrobial peptide which has been used worldwide for decades as a food preservative (E234). The chemical synthesis of orthogonally protected lanthionines and β -methylanthionines has been studied

extensively.⁴ Vederas has also reported on the replacement of the thioether bridge of lanthionines and β -methylanthionines with both carbon chain and oxygen bridged analogues.⁵




Figure 1. Structures of some cross-linking amino acids^{2,3}

We recently reported on our preliminary studies on extending the range of lanthionine thioether bridge replacements that are available by preparing orthogonally protected azalanthionines, which have an amine linker which should have quite different physicochemical properties to any of the other analogues (lanthionines, oxalanthionines or carbalanthionines), including water solubility at physiological pH.⁶ To date this is the only reported method for the preparation of orthogonally protected azalanthionines though a small number of reports on the synthesis of azalanthionines are known, but none gave orthogonally protected compounds which would be suitable for use in solid-phase peptide synthesis.⁷ The presence of a nitrogen atom in the cross-linker would also provide a very useful handle for further derivatisation, or conjugation, where required.

Thus, the goals of the current study were firstly to extend the range of orthogonally protected azalanthionines using our previously developed aziridine ring opening methodology. Our initial report demonstrated the viability of the methodology but only one azalanthionine analogue was prepared with the correct stereochemistry, when compared to stereochemistry of natural lanthionine containing peptides. For the

future incorporation of azalanthionines, in order to prepare lantibiotic analogues, a number of differentially protected analogues would be required with the desired stereochemistry. Since many lanthipeptides also contain the β -methylanthionine moiety, the second goal of this study was the extension of the methodology to prepare a range of β -methyl azalanthionines, again with the correct stereochemistry at each stereocentre.

2. Results and Discussion

2.1 Synthesis of orthogonally protected azalanthionines

The retrosynthetic analysis of the orthogonally protected azalanthionines shows that they could be prepared by ring-opening of N-activated aziridine-2-carboxylates with protected diaminopropionic acids (DAPs) (Figure 2). In turn the DAPs could be obtained by ring-opening of differently protected aziridines with *p*-methoxybenzylamine.






Figure 2. Retrosynthetic analysis of orthogonally protected azalanthionines

In order to prepare a range of different orthogonally protected azalanthionines suitable for solid-phase peptide synthesis the precursor N-activated aziridine-2-carboxylates were first prepared to explore the optimal substitution patterns for the synthesis of the required DAPs (Scheme 1). Starting with the known *N*-trityl aziridine-2-carboxylates, **1a** and **1b**,⁸ replacement of the trityl group with a number of electron-withdrawing groups gave the required N-activated aziridines (**2a-2c**, **3a-3c** and **7**). The regioselectivity of the ring-opening reaction, on treatment of the N-activated aziridines with *p*-methoxybenzylamine, was highly dependent on both the nature of the N-substituent and the ester group in the 2-position, as well as the temperature of the reaction.⁹ In all cases two molar equivalents of *p*-methoxybenzylamine was used.



Reagents and conditions; (a) See Supporting Information; (b) *p*-methoxybenzylamine (2 molar equiv.), MeCN, rt, 24 h.

Scheme 1. Synthesis of 1,2-diaminopropanoic acid derivatives (4-6)



Entry	Aziridine	Temp (°C)	% β-attack ^a	% α-attack ^a
1	2a (R = Me, EWG = Ts)	25	70 (4a)	23 (5a)
2		80	32 (4a)	41 (5a)
3	2b (R = Me, EWG = <i>p</i> -Ns)	25	42 (4b)	32 (5b)
4	2c (R = Me, EWG = <i>p</i> -Nz)	25	63 (4c)	-
5	3a (R = Allyl, EWG = Ts)	25 or 80 ^b	-	-
6	3b (R = Allyl, EWG = <i>p</i> -Ns)	25 or 80 ^b	-	-
7	3c (R = Allyl, EWG = <i>p</i> -Nz)	25	66 (6c)	-
10	7 (R = Allyl, EWG = alloc)	25 or 80 ^b	-	-


^a Product number is in parantheses; ^b No product from α- or β-attack obtained, even in the presence of BF₃·OEt₂ as Lewis acid catalyst.

Table 1. Regioselectivity of the ring-opening of N-activated aziridine-2-carboxylates with *p*-methoxybenzylamine

Aziridine **2a** gave a mixture of **4a** and **5a** in a 70:23 ratio at room temperature (Table 1, entry 1). However, the selectivity was reversed to give **4a** and **5a** in a 32:41 ratio, when the reaction was conducted at 80 °C (entry 2). Further reactions in this series were conducted at room temperature to maximise the yield of the product obtained from attack at the aziridine β-position. It was found that the *p*-Ns aziridine **2b** gave **4b**


and **5b** in a 63:21 ratio (entry 3). However, the *p*-Nz substituted aziridine **2c** only gave **4c**, the product of attack at the less hindered β -carbon of the aziridine in a 66% yield (entry 4). For the N-activated aziridine allyl esters **3a-c** (entries 5-7), only the N-*p*-Nz substituted derivative **3c** underwent reaction with *p*-methoxybenzylamine, with **6c** being obtained in a 66% yield, as the sole product. The *N*-alloc activated aziridine **7** gave no product from attack by *p*-methoxybenzylamine (entry 10). For the unsuccessful reactions, use of Lewis acid catalysis (boron trifluoride etherate) and/or heating to 80 °C, did not lead to any of the desired products. An examination of the results of the ring-opening reactions shows that the regioselective outcome is not predictable.⁹

Having prepared a number of the required DAPs they were then used to prepare orthogonally protected azalanthionines by ring-opening of the protected N-activated aziridines (Scheme 2). In these cases, it was found that there was no reaction observed at 25 °C, in the presence of 2 molar equivalents of the DAP. When the reactions were heated to 80 °C, only products from attack at the less sterically hindered aziridine β -position were obtained. It is most likely that this is due to the increased steric bulk of the secondary amine nucleophile of the DAP compared to the primary amino group of the *p*-methoxybenzylamine. Thus far a range of six diastereoisomeric azalanthionines (**8-12**, **17**) have been prepared using this methodology, with the stereochemistry of the diastereoisomer depending on whether L- or D-serine was used as the starting material for the precursor N-activated aziridines (Scheme 2 and Table 2).



Reagents and conditions; (a) **2b** (0.5 molar equiv.), MeCN, 80 °C, 24 h, (for **9** using **R-2b** (0.5 molar equiv.)); (b) **2a** (0.5 molar equiv.), MeCN, 80 °C, 24 h; (c) **2b** (0.5 molar equiv.), MeCN, 80 °C, 24 h, (for **12** using **R-2b** (0.5 molar equiv.)); (d) i) TMS-Cl, Et₃N, DCM; ii) Trt-Cl, Et₃N, MeOH, 58%; (e) i) Cs₂CO₃, MeOH; ii) allyl bromide, DMF, 91%; (f) Ref 10; (g) thiophenol, K₂CO₃, DMF, rt, 16 h, 80%; (h) **2a**, BF₃·OEt₂, CH₂Cl₂, rt, 24 h, 30%.

Scheme 2. Synthesis of azalanthionines (**8-12**, **17**)



Entry	Aziridine	DAP	% Azalanthionine ^a
1	S-2b (R ¹ = Me, P ¹ = <i>p</i> -Ns)	4a (R ² = Me, P ² = Ts)	46 (8 , (<i>S,S</i>))
2	R-2b (R ¹ = Me, P ¹ = <i>p</i> -Ns)		51 (9 , (<i>R,S</i>))
3	S-2a (R ¹ = Allyl, P ¹ = <i>p</i> -Nz)	6c (R ² = Me, P ² = <i>p</i> -Ns)	38 (10 , (<i>S,S</i>))
4	S-2b (R ¹ = Me, P ¹ = <i>p</i> -Ns)	6c (R ² = Me, P ² = <i>p</i> -Ns)	27 (11 , (<i>S,S</i>))
5	R-2b (R ¹ = Me, P ¹ = <i>p</i> -Ns)		32 (12 , (<i>R,S</i>))


^a % yield and stereochemistry in parantheses;

Table 2. Synthesis of orthogonally protected azalanthionines 8-12

The isolated yields of the azalanthionines, after aqueous workup, were 27-51%, which are comparable with those obtained for similar aziridine ring-opening reactions with protected cysteine or serine nucleophiles, used to prepare orthogonally protected lanthionines¹¹ and oxalanthionines.^{5b,c} The mass balance in each case was made up of the starting DAP and numbers of unidentified products which resembled ring-opened aziridines. These were possibly serine derivatives, though none were conclusively identified, either by NMR or mass spectrometric analysis. It also is worth mentioning that all of the synthesised azalanthionines were prone to decomposition when stored at ambient temperature. Simple TLC and HPLC analysis showed that they all decomposed to a multitude of products, particularly when stored in solution (results not shown). It was necessary to store them free of solvent in a freezer at -20 °C in order to increase their stability, but even in these cases they had almost completely decomposed in a matter of weeks. The reason for the instability is most likely due to the strongly electron-withdrawing protecting groups present on the nitrogen atoms, which increases the acidity of the α -hydrogens. This makes the molecules more prone to elimination most likely by a retro-Michael mechanism. Therefore, the same electron-withdrawing groups that are necessary for activation of the aziridine ring to nucleophilic ring-opening are also responsible for the instability of the resulting products.

Azalanthionine **12** is considered the most useful of those prepared, as it contained five orthogonal protecting groups. The next stage in the synthesis of aza analogues of lanthipeptides would involve the deprotection of *N-p-Nz* protecting group of **12** and replacement with a Fmoc group. Removal of the allyl group of the ester, with Pd(PPh₃)₄, would then give a carboxylic acid which could be attached to a resin for solid-phase peptide synthesis. Both of these deprotections have been successfully achieved by Vederas in the synthesis of analogues of the lanthipeptide lactacin 3147 A2, containing oxalanthionine linkers, so it is felt that these particular deprotections should also be possible for azalanthionine **12**. Furthermore the deprotection of the *N-Ns* group of DAP **15**, with thiophenol, has already been shown in the preparation of DAP **14**, in an isolated yield of 80% (Scheme 2).

As well as synthesising the azalanthionines two of the isomeric nor-azalanthionines (**18** and **19**) were also prepared (Scheme 3). This was achieved by treating the same N-activated aziridine-2-carboxylates (**2a** and **2b**) with the β -amino acid **5a**, which had been obtained as a by-product from attack of *p*-methoxybenzylamine at the α -position of the aziridines (Scheme 1). Again, in these cases, only attack at the less hindered β -position occurred to give nor-azalanthionines **18** and **19**, in 47% and 39% yields, respectively. The success of these reactions was somewhat surprising because of the highly hindered nature of the secondary amine nucleophiles used.



Reagents and conditions; (a) **2a** (2 molar equiv.), MeCN, 80 °C, 24 h, 47%; (b) **2b** (2 molar equiv.), MeCN, 80 °C, 24 h, 39%;


Scheme 3. Synthesis of isomeric nor-azalanthionines (18 and 19)

2.2 Routes towards β -methyl azalanthionines

Having successfully prepared orthogonally protected azalanthionines attempts were then made to extend the methodology to the β -methyl azalanthionines, which are the amine-linked analogues of the known β -methyllanthionines and β -methyl oxalanthionines.⁵ For the retrosynthesis of the β -methyl azalanthionines two simple disconnections were envisaged (Figure 3). Disconnection **A** would give a route involving ring-opening of N-activated 3-methyl-aziridine-2-carboxylates with the previously prepared DAP derivatives. The aziridines would come from suitably protected threonine derivatives, as starting materials. The alternative disconnection **B** would give N-activated 3-unsubstituted-aziridine-2-carboxylates and β -methyl DAPs. It was envisaged that the required β -methyl DAPs would, in turn, be prepared by ring-


catalysis, with $\text{BF}_3 \cdot \text{OEt}_2$ in dichloromethane at reflux temperature, again gave none of the required products.

Using the successful synthesis of the nor-azalanthionines by ring-opening of an aziridine with a relatively hindered secondary amine as a model, the synthesis of the β -methyl azalanthionines was then attempted by reaction of β -methyl DAPs with *N*-activated 3-unsubstituted aziridines. The β -methyl DAPs were prepared by ring-opening of the β -methyl aziridines (**21a-c** and **22a-c**) with *p*-methoxybenzylamine (Scheme 4). For example, when aziridine **21a** was reacted with *p*-methoxybenzylamine (2 molar equivalents) at room temperature in acetonitrile, again two regioisomers were obtained in a combined yield of 76% (Table 3, entry 2). In this case almost equal amounts of both regioisomers were isolated, with the product from β -attack (**23a**) being obtained in 41%, while that from α -attack (**24a**) was obtained in 35% yield. When the reaction was repeated at reflux temperature the ratio was \sim 4:1 in favour of the product from α -attack (entry 3). When the reaction was conducted at 0 °C, the ratio was \sim 1:1 (entry 1, 34% for β -attack and 32% for α -attack). All the other *N*-activated 3-methyl aziridines previously synthesised were then reacted with *p*-methoxybenzylamine at different temperatures (Table 3).



Reagents and conditions; (a) Ref 8; (b) see Scheme 2; (c) *p*-methoxybenzylamine (2 molar equiv.), MeCN, 24 h.

Scheme 4. Synthesis of β -methyl DAPs



Entry	Aziridine	Temp (°C)	% β -attack ^a	% α -attack ^a
1	21a (R = Me, EWG = Ts)	0	34 (23a)	32 (24a)
2		25	41 (23a)	35 (24a)
3		80	15 (23a)	62 (24a)
4	19b (R = Me, EWG = <i>p</i> -Ns)	0	42 (23b)	32 (24b)
5		25	27 (23b)	55 (24b)
6		80	21 (23b)	61 (24b)
7	19c (R = Me, EWG = <i>p</i> -Nz)	NR ^b	-	-
8	20a (R = Allyl, EWG = Ts)	0	38 (25a)	-
9		25	42 (25a)	-
10		80 ^c	-	-
11	20b (R = Allyl, EWG = <i>p</i> -Ns)	0	43 (25b)	35 (26b)
12		25	21 (25b)	49 (26b)
13		80 ^c	-	-
14	20c (R = Allyl, EWG = <i>p</i> -Nz)	0	39 (25c)	-
15		25	27 (25c)	-
16		80 ^c	-	-

^a Product number is in parantheses; ^b No reaction when conducted at 0 °C, 25 °C or 80 °C; ^cNo product from α - or β -attack obtained.

Table 3: Regioselectivity of the ring-opening of 3-methyl-aziridines with *p*-methoxybenzylamine

When aziridine **21b** was used similar results were obtained (entries 4-6), except for the reaction conducted at 25 °C, where the product of α -attack (55% **24b**) was obtained in preference to the product of β -attack (27%, **23b**). Surprisingly, when aziridine **21c**, which contains the *N-p*-Nz group, was used no products from attack at either the α - or β -positions were obtained at any of the temperatures studied (entry 7). This is in contrast to our previous study which showed that the 3-unsubstituted *N-p*-Nz aziridine methyl ester (**2c**) gave the product from attack at the β -position (**4c**) as the sole product in a 63% isolated yield.⁹ This study had found that when the ester group was changed from methyl to allyl only the 3-unsubstituted aziridine with a *N-p*-

Nz activating group underwent a ring-opening reaction with *p*-methoxybenzylamine, giving the product of β -attack (**6c**) as the sole product in 66% yield. However, when the corresponding 3-methyl substituted aziridines were used strikingly different results were obtained (entries 8-16). In all cases, reactions conducted at 80 °C did not give any products from attack at the α or β positions. For aziridines **22a** and **22c** only β -attack was observed, but for **22b** products from both α - and β -attack were isolated. As for the case of the 3-unsubstituted aziridines the regioselectivity is highly unpredictable. A computational study of both the 3-substituted and 3-unsubstituted aziridine derivatives is currently being undertaken in order to try to explain the observed regioselectivity outcomes.

With a selection of the required β -methyl DAPs (**23a**, **23b**, **25a-c**) in hand, an attempt was made to ring-open the 3-unsubstituted aziridines (**2a-c** and **3a-c**) under reflux conditions in acetonitrile. A significant number of different combinations were tried but there was no evidence, in any case, for the desired β -methyl azalanthionines. In every reaction only the starting β -methyl DAPs were recovered after aqueous workup, along with compounds which appeared to be derived from opening of the aziridine ring, as evidenced by the appearance of their NMR spectra compared with, for example, aziridine ring-opened precursors. As before, the use of $\text{BF}_3 \cdot \text{OEt}_2$ in dichloromethane at reflux temperature was also unsuccessful. These results were somewhat surprising owing to the successful synthesis of the nor-lanthionines **18** and **19**, using what appeared to be an even more sterically demanding secondary amine nucleophile.

3. Conclusions

The synthesis of a range of orthogonally protected azalanthionines, which are amine linked analogues of the increasingly important lanthionine-containing bioactive peptides, has been achieved by ring opening of N-activated 3-unsubstituted aziridines with protected DAPs. However, the azalanthionines are unstable to storage at ambient temperature, most probably due to the strongly electron-withdrawing nitrogen substituents. Extension of the methodology to the preparation of β -methyl azalanthionines has not been achieved so far. This was attempted by two methods

which involved i) reaction of DAPs with N-activated 3-methyl-substituted aziridines, or ii) reaction of β -methyl DAPs with N-activated 3-unsubstituted aziridines. In all cases, there was no indication of the formation of desired β -methyl azalanthionines, even by mass spectrometry. It has also been found that the regioselectivity of the ring opening of N-activated aziridine-2-carboxylates with *p*-methoxybenzylamine is not predictable.

4. Experimental

4.1 General

All isolated products were purified using column chromatography with silica gel (Aldrich, 70-230 mesh, 60 Å) in the indicated solvent systems. Melting points were determined with Stuart scientific SMP1 & Mettler FP62 melting point apparatus. Analytical thin layer chromatography (TLC) was performed on pre-coated plates (Merck Kieselgel 60 F₂₅₄) and visualised with UV light (254 nm), iodine vapour or aqueous potassium permanganate solution. Infrared spectra were recorded as KBr disks or a thin film between sodium chloride plates, on Avatar 320 and Nicolet impact 410 FT-IR spectrophotometers, run on EZ Omnic E.S.P 5.2a and 3.1a software packages, respectively. Polarimetry was carried out using an Optical Activity AA-55 series polarimeter at ambient temperature with a 2 dm, 1 ml cell. ¹H NMR and ¹³C NMR spectra were measured on a JOEL JNM-LA300 FT-NMR or a Bruker Avance III 500 MHz FT-NMR with TopSpin 2.16 Software and 5mm PATXI 1H/13-C/15N Z-GRD probe, in CDCl₃ as solvent. Chemical shift values are reported relative to tetramethylsilane. Mass Spectrometry was carried out at the Centre for Synthesis and Chemical Biology in University College Dublin using Quattro *micro*TM LC-MS/MS and Liquid chromatography time-of-flight (LCT) mass spectrometers. Exact Mass Spectrometry analyses were carried out at the Department of Chemistry, NUI Maynooth, Co. Kildare, Ireland.

Experimental Procedures 4.2

General procedure for ring-opening of aziridines with *p*-methoxybenzylamine for the preparation of DAPs 4a-c and 6c.

To a solution of the relevant aziridine (2 mmol) in acetonitrile (5 ml) was added *p*-methoxybenzylamine (0.52 ml, 4 mmol) and the solution was stirred for 24 h at room temperature. The solvent was removed *in vacuo*, and then the residue was redissolved in ethyl acetate (20 ml), washed with brine (2 x 20 ml), dried over anhydrous magnesium sulfate and concentrated *in vacuo*. The crude product was purified by flash column chromatography on silica gel in petroleum ether:ethyl acetate (2:1).

(*S*)-Methyl 3-(4-methoxybenzylamino)-2-(4-methylphenylsulfonamido) propanoate (**4a**). Colourless oil (0.54 g, 70%); R_f : 0.12 petroleum ether:ethyl acetate (1:1); $[\alpha]_D^{20} = +13.35^\circ$ (*c* 1.0 in CHCl_3); $^1\text{H NMR}$ (CDCl_3 , δ ppm) 7.72 (d, 2H, $J = 8.8$ Hz), 7.28 (d, 2H, $J = 8.8$ Hz), 7.16 (d, 2H, $J = 8.8$ Hz), 6.85 (d, 2H, $J = 8.8$ Hz), 4.03 (t, 1H, $J = 4.8$ Hz), 3.79 (s, 3H), 3.65 (d, 1H, $J = 12.9$ Hz), 3.61 (d, 1H, $J = 12.9$ Hz), 3.52 (s, 3H), 2.88 (d, 2H, $J = 5.2$ Hz), 2.40 (s, 3H); $^{13}\text{C NMR}$ (CDCl_3 , δ ppm) 171.2, 158.7, 143.7, 136.6, 131.3, 129.6, 129.3, 127.2, 113.8, 60.4, 55.3, 52.6, 52.3, 50.0, 21.5; IR (thin film, cm^{-1}) 3347, 3089, 2981, 1744, 1188, 1150; HRMS (ES+) calculated for $\text{C}_{19}\text{H}_{25}\text{N}_2\text{O}_5\text{S}$, $[\text{M}+\text{H}]^+$ 393.1479, found $[\text{M}+\text{H}]^+$ 393.1477.

(*S*)-Methyl 3-(4-methoxybenzylamino)-2-(4-nitrophenylsulfonamido) propanoate (**4b**). Pale yellow oil (0.53 g, 42%); R_f : 0.20 petroleum ether:ethyl acetate (1:1); $[\alpha]_D^{20} = +16.51^\circ$ (*c* 1.0 in CHCl_3); $^1\text{H NMR}$ (CDCl_3 , δ ppm) 8.32 (d, 2H, $J = 9.0$ Hz), 8.02 (d, 2H, $J = 9.0$ Hz), 7.16 (d, 2H, $J = 8.7$ Hz), 6.86 (d, 2H, $J = 8.7$ Hz), 4.11 (t, 1H, $J = 6.1$ Hz), 3.80 (s, 3H), 3.65 (s (br), 2H), 3.58 (s, 3H), 3.01-2.86 (dd, 2H, $J = 5.0, 4.9$ Hz); $^{13}\text{C NMR}$ (CDCl_3 , δ ppm) 170.7, 158.9, 150.0, 145.8, 131.2, 129.5, 128.3, 124.4, 113.8, 55.5, 55.3, 52.8, 52.6, 49.9; IR (thin film, cm^{-1}) 3375, 3087, 2981, 1743, 1552, 1381, 1177; HRMS (ES+) calculated for $\text{C}_{18}\text{H}_{22}\text{N}_3\text{O}_7\text{S}$, $[\text{M}+\text{H}]^+$ 438.1329, found $[\text{M}+\text{H}]^+$ 438.1322.

(*S*)-Methyl 3-(4-methoxybenzylamino)-2-((4-nitrobenzyloxy)carbonylamino) propanoate (**4c**). Pale yellow oil (0.46 g, 63%); R_f : 0.22 petroleum ether:ethyl acetate (1:1); $[\alpha]_D^{20} = +22.48^\circ$ (*c* 1.0 in CHCl_3); $^1\text{H NMR}$ (CDCl_3 , δ ppm) 8.20 (d, 2H, $J = 8.7$ Hz), 7.50 (d, 2H, $J = 8.7$ Hz), 7.20 (d, 2H, $J = 8.6$ Hz), 6.86 (d, 2H, $J = 8.6$ Hz), 5.19 (d, 2H, $J = 8.6$ Hz), 4.43 (m, 1H), 3.78 (s, 3H), 3.75 (s (br), 2H), 3.72 (s, 3H), 3.10-2.98 (dd, 2H, $J = 4.8, 4.8$ Hz); $^{13}\text{C NMR}$ (CDCl_3 , δ ppm) 171.3, 158.8, 155.3, 147.5,

143.6, 130.9, 129.5, 128.0, 123.7, 113.6, 65.3, 55.1, 53.5, 52.6, 52.3, 49.1; IR (thin film, cm^{-1}) 3341, 3065, 2981, 1744, 1680, 1212; HRMS (ES+) calculated for $\text{C}_{20}\text{H}_{24}\text{N}_3\text{O}_7$, $[\text{M}+\text{H}]^+$ 418.1609, found $[\text{M}+\text{H}]^+$ 418.1627.

(R)-Methyl 2-(4-methoxybenzylamino)-3-(4-methoxyphenylsulfonamido) propanoate (**5a**). Colourless oil (0.17 g, 41%); R_f : 0.24 petroleum ether:ethyl acetate (1:1); $[\alpha]_D^{20} = +12.41^\circ$ (c 1.0 in CHCl_3); ^1H NMR (CDCl_3 , δ ppm) 7.70 (d, 2H, $J = 8.6$ Hz), 7.28 (d, 2H, $J = 8.0$ Hz), 7.15 (d, 2H, $J = 8.6$ Hz), 6.85 (d, 2H, $J = 8.6$ Hz), 5.15 (s (br), 1H) 3.80 (s, 3H), 3.68 (s, 3H), 3.65 (m, 2H), 3.51(d, 1H, $J = 12.9$ Hz), 3.30 (m, 1H), 3.26 (dd, 1H, $J = 8.6, 8.6$ Hz), 2.95 (dd, 1H, $J = 7.5, 7.4$ Hz); ^{13}C NMR (CDCl_3 , δ ppm) 172.9, 158.9, 143.5, 136.6, 131.0, 129.7, 129.4, 127.0, 113.9, 59.0, 55.3, 52.3, 51.2, 44.2, 21.5; IR (thin film, cm^{-1}) 3359, 3082, 2991, 1743, 1224, 1124.

(R)-Methyl 2-(4-methoxybenzylamino)-3-(4-nitrophenylsulfonamido) propanoate (**5b**). Pale yellow oil (0.17 g, 32%); R_f : 0.32 petroleum ether:ethyl acetate (1:1); ^1H NMR (CDCl_3 , δ ppm) 8.28 (d, 2H, $J = 9.0$ Hz), 7.94 (d, 2H, $J = 9.0$ Hz), 7.14 (d, 2H, $J = 8.7$ Hz), 6.83 (d, 2H, $J = 8.7$ Hz), 3.80 (s, 3H), 3.71 (s, 3H), 3.65 (d, 1H, $J = 12.9$ Hz), 3.54 (d, 1H, $J = 12.9$ Hz), 3.30-3.26 (m, 2H), 3.05 (m, 1H); ^{13}C NMR (CDCl_3 , δ ppm) 172.5, 159.0, 149.9, 145.6, 130.8, 129.4, 128.2, 124.4, 113.9, 59.2, 55.5, 52.6, 51.3, 44.3; IR (thin film, cm^{-1}) 3401, 3065, 2971, 1745, 1542, 1371, 1196.

(S)-Allyl 3-(4-methoxybenzylamino)-2-((4-nitrobenzyloxy) carbonylamino) propanoate (**6c**). Pale yellow oil (0.58 g, 66%); R_f : 0.11 petroleum ether:ethyl acetate (1:1); $[\alpha]_D^{20} = +26.25^\circ$ (c 1.0 in CHCl_3); ^1H NMR (CDCl_3 , δ ppm) 8.21 (d, 2H, $J = 8.7$ Hz), 7.51 (d, 2H, $J = 8.7$ Hz), 7.19 (d, 2H, $J = 8.6$ Hz), 6.86 (d, 2H, $J = 8.6$ Hz), 5.89 (m, 2H), 5.36-5.16 (m, 4H), 4.65 (d, 2H, $J = 5.9$ Hz), 4.43 (m, 1H), 3.79 (s, 3H), 3.70 (s (br), 2H), 3.10-2.96 (dd, 2H, $J = 5.8, 5.7$ Hz); ^{13}C NMR (CDCl_3 , δ ppm) 171.1, 158.8, 155.6, 147.6, 143.8, 131.6, 131.4, 129.2, 128.0, 123.7, 118.9, 113.8, 66.1, 65.4, 55.2, 54.1, 53.1, 49.5; IR (thin film, cm^{-1}) 3367, 3075, 2976, 1743, 1674; HRMS (ES+) calculated for $\text{C}_{22}\text{H}_{26}\text{N}_3\text{O}_7$, $[\text{M}+\text{H}]^+$ 444.1765, found $[\text{M}+\text{H}]^+$ 444.1754.

(*S*)-Methyl 3-(((*S*)-3-methoxy-2-(4-methylphenylsulfonamido)-3-oxopropyl)(4-methoxybenzyl)amino)-2-(4-nitrophenylsulfonamido) propanoate (**8**). *N*-*p*-nosyl aziridine methyl ester **2b** (0.07 g, 0.25 mmol) was dissolved in MeCN (5 ml) before adding DAP **4a** (0.2 g, 0.5 mmol, 2 eq.) and the solution was stirred at reflux temperature for 24 h before removing the solvent *in vacuo*. The oil was dissolved in ethyl acetate (20 ml), washed with brine (2 x 20 ml) and dried over anhydrous magnesium sulfate before removing the solvent *in vacuo*. The crude product was purified by preparative TLC on silica gel (petroleum ether:ethyl acetate 4:1) to yield **8**, as a pale yellow oil (0.08 g, 46%). *R*_f: 0.37 petroleum ether:ethyl acetate (1:1); ¹H NMR (CDCl₃, δ ppm) 8.33 (d, 2H, *J* = 8.8 Hz), 8.07 (d, 2H, *J* = 8.8 Hz), 7.70 (d, 2H, *J* = 8.4 Hz), 7.32 (d, 2H, *J* = 8.3 Hz), 7.08 (d, 2H, *J* = 8.4 Hz), 6.80 (d, 2H, *J* = 8.4 Hz), 6.20 (s (br), 1H), 4.19 (t, 1H, *J* = 5.3 Hz), 4.03 (dd, 2H, *J* = 7.8 Hz, 6.5 Hz) 3.79 (s, 3H), 3.74 (d, 1H, *J* = 13.4 Hz), 3.50 (d, 1H, *J* = 13.4 Hz), 3.46 (s, 3H), 3.41 (s, 3H), 2.97 (m, 3H), 2.71 (m, 1H), 2.40 (s, 3H); ¹³C NMR (CDCl₃, δ ppm) 171.0, 170.7, 159.0, 149.8, 146.3, 143.7, 136.5, 130.7, 130.5, 129.8, 128.5, 127.2, 124.1, 113.9, 58.4, 56.7, 56.2, 55.1, 55.1, 52.68, 52.63, 21.6; IR (thin film, cm⁻¹) 3356, 3089, 2982, 1744, 1732, 1532, 1379, 1173, 1133.

(*S*)-Methyl 3-(((*R*)-3-methoxy-2-(4-methylphenylsulfonamido)-3-oxopropyl)(4-methoxybenzyl)amino)-2-(4-nitrophenylsulfonamido) propanoate (**9**). **9** was synthesised using a similar method to that used to synthesise **8**, except the protected aziridine *R*-**2b** was used (0.07 g, 0.25 mmol). The crude product was purified by preparative TLC on silica gel (petroleum ether:ethyl acetate 4:1) to yield **9** as a pale yellow oil (0.09 g, 51%). *R*_f: 0.18 petroleum ether:ethyl acetate (1:1); [α]_D²⁰ = +32.96° (*c* 1.0 in CHCl₃); ¹H NMR (CDCl₃, δ ppm) 8.34 (d, 2H, *J* = 8.7 Hz), 8.06 (d, 2H, *J* = 8.7 Hz), 7.73 (d, 2H, *J* = 8.4 Hz), 7.28 (d, 2H, *J* = 8.3 Hz), 7.13 (d, 2H, *J* = 8.5 Hz), 6.82 (d, 2H, *J* = 8.5 Hz), 4.14 (d, 1H, *J* = 6.5 Hz), 4.06 (dd, 1H, *J* = 7.0, 6.2 Hz), 3.81 (d, 1H, *J* = 12.9 Hz), 3.80 (s, 3H), 3.50 (d, 1H, *J* = 12.9 Hz), 3.46 (s, 3H), 3.41 (s, 3H), 3.02 (m, 3H), 2.76 (m, 1H), 2.42 (s, 3H); ¹³C NMR (CDCl₃, δ ppm) 171.1, 170.8, 159.1, 149.9, 146.1, 143.8, 136.6, 130.8, 130.6, 129.6, 128.4, 127.2, 124.1, 113.8, 58.4, 56.7, 56.2, 55.2, 55.1, 52.7, 52.6, 21.6; IR (thin film, cm⁻¹) 3350, 3081, 2985, 1744, 1732, 1537, 1381, 1177, 1143; HRMS (ES⁺) calculated for C₂₉H₃₅N₄O₁₁S₂, [M+H]⁺ 679.1738, found [M+H]⁺ 679.1748.

(*S*)-Allyl 3-(((*R*)-3-methoxy-2-(4-methylphenylsulfonamido)-3-oxopropyl)(4-methoxybenzyl)amino)-2-((4-nitrobenzyloxy)carbonylamino) propanoate (**10**). **10** was synthesised using a similar method to that used to synthesise **8**, except the protected aziridine *R*-**2a** was used (0.06 g, 0.25 mmol) and the protected DAP was **6c** (0.22 g, 0.5 mmol, 2 eq.). The crude product was purified by preparative TLC on silica gel (petroleum ether:ethyl acetate 4:1) to yield **10** as a pale yellow oil (0.06 g, 38%). R_f: 0.18 petroleum ether:ethyl acetate (1:1); [α]_D²⁰ = +21.31° (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, δ ppm) 8.21 (d, 2H, *J* = 8.3 Hz), 7.72 (d, 2H, *J* = 8.3 Hz), 7.57 (d, 2H, *J* = 8.0 Hz), 7.27 (d, 2H, *J* = 8.0 Hz), 7.11 (d, 2H, *J* = 8.6 Hz), 6.77 (d, 2H, *J* = 8.6 Hz), 5.88 (m, 2H), 5.79 (d, 1H, *J* = 8.2 Hz), 5.29 (m, 4H), 4.60 (pseudo t, 2H, *J* = 5.7 Hz), 4.43 (dd, 1H, *J* = 8.2, 8.1 Hz), 4.14 (m, 1H), 3.77 (s, 3H), 3.70 (d, 1H, *J* = 12.9 Hz), 3.51 (s, 3H), 3.33 (d, 1H, *J* = 13.0 Hz), 2.90-2.73 (m, 4H), 2.41 (s, 3H); ¹³C NMR (CDCl₃, δ ppm) 170.9, 170.6, 159.0, 156.0, 147.5, 143.9, 143.5, 137.1, 131.2, 130.5, 129.5, 129.2, 128.1, 127.1, 123.7, 119.3, 113.7, 66.6, 65.6, 57.6, 55.7, 55.4, 55.2, 54.3, 52.7, 52.4, 21.5; IR (thin film, cm⁻¹) 3401, 3083, 2971, 1749, 1737, 1671, 1386, 1249; HRMS (ES⁺) calculated for C₃₃H₃₉N₄O₁₁S, [M+H]⁺ 699.2331, found [M+H]⁺ 699.2321.

(*S*)-Allyl 3-(((*S*)-3-methoxy-2-(4-nitrophenylsulfonamido)-3-oxopropyl)(4-methoxybenzyl)amino)-2-((4-nitrobenzyloxy)carbonylamino) propanoate (**11**). **11** was synthesised using a similar method to that used to synthesise **8**, except the protected aziridine **2b** was used (0.07 g, 0.25 mmol) and the protected DAP was **6c** (0.22 g, 0.5 mmol, 2 eq.). The crude product was purified by preparative TLC on silica gel in petroleum ether:ethyl acetate 4:1, to yield **11** as a pale yellow oil (0.05 g, 27%). R_f: 0.22 petroleum ether:ethyl acetate (1:1); ¹H NMR (CDCl₃, δ ppm) 8.30 (d, 2H, *J* = 8.8 Hz), 8.22 (d, 2H, *J* = 8.1 Hz), 8.00 (d, 2H, *J* = 8.8 Hz), 7.54 (d, 2H, *J* = 8.1 Hz), 7.10 (d, 2H, *J* = 8.1 Hz), 6.81 (d, 2H, *J* = 8.1 Hz), 6.24 (s (br), 1H), 5.94 (m, 1H), 5.43-5.24 (m, 5H), 4.60 (m, 2H, *J* = 5.6 Hz), 4.48-4.34 (m, 1H), 4.14 (m, 1H), 3.78 (s, 3H), 3.76 (d, 1H, *J* = 13.2 Hz), 3.51 (s, 3H), 3.46 (d, 1H, *J* = 13.2 Hz), 2.98-2.85 (m, 2H), 2.78-2.71 (m, 2H); ¹³C NMR (CDCl₃, δ ppm) 170.6, 170.2, 159.2, 156.2, 149.9, 147.8, 146.5, 143.4, 132.4, 131.1, 130.4, 128.3, 128.1, 123.9, 123.7, 119.5, 113.9, 66.5, 65.9, 57.7, 56.6, 55.2, 54.9, 54.1, 52.8, 52.4; IR (thin film, cm⁻¹) 3347, 3074, 2991, 1749, 1733, 1677, 1547, 1386, 1192.

(*S*)-Allyl 3-(((*R*)-3-methoxy-2-(4-nitrophenylsulfonamido)-3-oxopropyl)(4-methoxybenzyl)amino)-2-((4-nitrobenzyloxy)carbonylamino) propanoate (**12**). **12** was synthesised using a similar method to that used to synthesise **8**, except the protected aziridine used was *R*-**2b** (0.07 g, 0.25 mmol). The crude product was purified by preparative TLC on silica gel in petroleum ether:ethyl acetate 4:1, to yield **12** as a pale yellow oil (0.06 g, 32%). R_f : 0.22 petroleum ether:ethyl acetate (1:1); $[\alpha]_D^{20} = +67.20^\circ$ (*c* 1.0 in CHCl_3); $^1\text{H NMR}$ (CDCl_3 , δ ppm) 8.30 (d, 2H, $J = 8.8$ Hz), 8.26 (d, 2H, $J = 8.6$ Hz), 8.06 (d, 2H, $J = 8.8$ Hz), 7.57, (d, 2H, $J = 8.9$ Hz), 7.14 (d, 2H, $J = 8.1$ Hz), 6.78 (d, 2H, $J = 8.1$ Hz), 6.51 (s (br), 1H), 5.86 (m, 1H), 5.34-5.22 (m, 5H), 4.60 (m, 2H), 4.44 (pseudo t, 1H, $J = 4.8$ Hz), 4.30 (pseudo t, 1H, $J = 4.9$ Hz), 3.77 (d, 1H, $J = 13.2$ Hz), 3.76 (s, 3H), 3.51 (s, 3H), 3.46 (d, 1H, $J = 13.2$ Hz), 2.94-2.88 (m, 2H), 2.76, (d, 2H, $J = 6.2$ Hz); $^{13}\text{C NMR}$ (CDCl_3 , δ ppm) 170.6, 170.2, 159.2, 156.2, 149.9, 147.8, 146.5, 143.4, 132.4, 131.1, 130.4, 128.3, 128.1, 123.9, 123.7, 119.5, 113.9, 66.5, 65.9, 57.7, 56.6, 55.2, 54.9, 54.1, 52.8, 52.4; IR (thin film, cm^{-1}) 3359, 3079, 2998, 1748, 1734, 1678, 1551, 1381, 1199.

N-Triphenylmethyl-(*S*)-serine (**13**). To a suspension of *S*-serine (2.0 g, 18 mmol) in DCM (26 ml) under a nitrogen atmosphere, was added Me_3SiCl (7.5 ml, 57 mmol) and the solution was stirred at reflux temperature for 20 min. The solution was allowed to cool to 0 °C and Et_3N (8.3 ml, 57 mmol) in DCM (26 ml) was added dropwise over 10 min. to the solution which was then stirred for 45 min. The solution was cooled to 0 °C and anhydrous methanol (0.9 ml) was added dropwise. The solution was allowed to warm to room temperature, and Et_3N (7.0 ml, 18 mmol) was added followed by triphenylmethyl chloride (4.6 g, 18 mmol), and the solution was stirred for 20 h at ambient temperature. An excess of Et_3N (13 ml) and then methanol (94 ml) was added until the white solid present in the mixture was dissolved. The excess solvent was then removed *in vacuo* producing a white solid. The white solid was partitioned between ethyl acetate (67 ml) and citric acid (40.2 ml, 5% aq. w/v), which had been pre-cooled to 4 °C. The organic layer was washed with 2 M aqueous sodium hydroxide (2 x 20 ml) followed by water (3 x 15 ml). The aqueous layers were combined, washed with ethyl acetate (15 ml) and neutralised with glacial acetic acid (3-4 ml) at 0 °C. The precipitated product was extracted with ethyl acetate (6 x 30 ml) and the organic layer was dried over anhydrous magnesium sulfate. The solvent was removed *in vacuo* to produce a white solid (3.1 g, 48%). M.pt. 109-110

°C; ^1H NMR (CDCl_3 , δ ppm) 7.43 (d, 6H, $J = 6.0$ Hz), 7.32-7.29, 7.28 (m, 3H), 3.73-3.71 (m, 1H), 3.50 (dd, 1H, $J = 2.9, 2.9$ Hz), 2.94-2.90 (m, 1H); ^{13}C NMR (CDCl_3 , δ ppm) 174.9, 145.2, 129.3, 128.6, 126.2, 73.9, 67.5, 62.0; IR (KBr, cm^{-1}) 3314, 3068, 1732.

The enantiomeric *N*-trityl-(*R*)-serine (**R-13**) was also prepared in a similar manner from (*R*)-serine.

N-Triphenylmethyl-(*S*)-serine allyl ester (**14**). *N*-Triphenylmethyl-(*S*)-serine (0.30 g, 0.87 mmol) was converted to its cesium salt by dissolving it in dry methanol (3.0 ml) containing Cs_2CO_3 (0.15 g, 0.45 mmol) under a nitrogen atmosphere. After removing the solvent *in vacuo*, the salt produced was re-dissolved in DMF (0.6 ml) and the resulting mixture was treated with allyl bromide (0.10 ml, 0.90 mmol). The solution was left stirring for a further 18 h at ambient temperature, after which the DMF was removed *in vacuo*. The mixture was then re-dissolved in ethyl acetate (3 ml) and washed with citric acid solution (1 x 10 ml, 5% aq. w/v). The aqueous layers were combined and extracted with ethyl acetate (2 x 10 ml), and the organic layers were combined and washed with water (12 x 10 ml). The organic layer was dried over anhydrous magnesium sulfate and the solvent was removed *in vacuo* producing a brown oil (0.30 g, 90%). R_f 0.73, hexane:ethyl acetate (2:1); ^1H NMR (CDCl_3 , δ ppm) 7.50 (dd, 6H, $J = 8.4, 5.3$ Hz), 7.25-7.22 (m, 9H), 5.70-5.67 (m, 1H), 5.18 (dd, 1H, $J = 1.5, 1.3$ Hz), 5.13 (dd, 1H, $J = 1.5, 1.5$ Hz), 4.19-4.17 (m, 1H), 4.09-4.00 (m, 1H), 3.72 (dd, 1H, $J = 6.6, 6.4$ Hz), 3.54 (dd, 2H, $J = 4.2, 3.9$ Hz); ^{13}C NMR (CDCl_3 , δ ppm) 173.1, 145.1, 131.6, 128.7, 127.9, 126.6, 118.4, 71.0, 65.7, 64.9, 57.8; IR (thin film, cm^{-1}) 3477, 3068, 2960, 1740, 1635.

The enantiomeric **R-14** was also prepared in a similar manner from *N*-trityl-(*R*)-serine.

2-(*S*)-Allyloxycarbonylamino-3-[(4-methoxy-benzyl)-(2-nitro-benzenesulfonyl)-amino]-propionic acid allyl ester (**15**). To a solution of *N*-(*p*-methoxybenzyl)-2-nitrobenzenesulfonamide¹⁰ (0.22 g, 0.70 mmol) in THF (3 ml) was added PPh_3 (0.34 g, 1.4 mmol), followed by the addition of *N*-triphenylmethyl-(*S*)-serine allyl ester (0.16 g, 1.4 mmol) and then diethyl azodicarboxylate (0.19 g, 1.2 mmol). The resulting mixture was allowed to stir at room temperature, under a nitrogen

atmosphere, for 10 h. The solvent was removed *in vacuo* giving an orange oil. Purification by flash column chromatography on silica gel in petroleum ether:ethyl acetate (4:1) gave *3-[(4-Methoxybenzyl)-(2-nitrobenzenesulfonyl)-amino]-2-(S)-(tritylamino)propanoic acid allyl ester* as a white solid (0.23 g, 51%). R_f 0.36, petroleum ether:ethyl acetate (2:1); M.pt. 85-87 °C; ^1H NMR (CDCl_3 , δ ppm) 8.01 (dd, 1H, $J = 4.6, 4.4$ Hz), 7.89 (dd, 1H, $J = 5.1, 5.1$ Hz), 7.65 (m, 6H), 7.50-7.40 (m, 2H), 7.24-7.16 (m, 9H), 7.00 (d, 2H, $J = 8.7$ Hz), 6.70 (d, 2H, $J = 8.7$ Hz), 5.64-5.60 (m, 1H), 5.34 (m, 1H), 5.13 (dd, 2H, $J = 10.2, 10.1$ Hz), 4.46 (s, 2H), 4.34 (dd, 2H, $J = 7.1, 6.9$ Hz), 3.95-3.90 (m, 1H), 3.80 (s, 3H), 3.79-3.55 (m, 2H); ^{13}C NMR (CDCl_3 , δ ppm) 169.2, 159.3, 145.5, 145.0, 135.2, 134.0, 132.6, 131.1, 130.1, 129.6, 129.3, 128.0, 126.5, 125.2, 124.2, 118.8, 114.0, 67.2, 64.2, 55.3, 55.0, 49.9, 47.4. IR (KBr, cm^{-1}) 3347, 3163, 2901, 1721, 1605, 1561, 1130. MS (ES^+) calculated for $\text{C}_{39}\text{H}_{37}\text{N}_3\text{O}_7\text{S}$, $[\text{M}+\text{H}]^+$ 692.2, found $[\text{M}+\text{H}]^+$ 692.1.

3-[(4-Methoxybenzyl)-(2-nitrobenzenesulfonyl)-amino]-2-(S)-(tritylamino)propanoic acid allyl ester (0.10 g, 0.16 mmol) was treated with 50% TFA in CHCl_3 (2.2 ml), under a nitrogen atmosphere, for 1 h. NaHCO_3 (0.10 g, 2.2 mmol) was added with water (5 ml) and stirred for 5 min, then further NaHCO_3 (0.10 g, 2.2 mmol) was added followed by allyl chloroformate (0.5 ml, 0.5 mmol). The mixture was stirred at room temperature for 12 h, diluted with ethyl acetate (20 ml) and washed with water (2 x 10 ml), dried over magnesium sulfate, and concentrated *in vacuo* producing a yellow oil. Purification by flash column chromatography on silica gel in petroleum ether:ethyl acetate (4:1) gave **15** as a yellow oil (0.050 g, 63%). R_f 0.57, petroleum ether:ethyl acetate (1:2); ^1H NMR (CDCl_3 , δ ppm) 7.99 (d, 1H, $J = 7.3$ Hz), 7.69-7.60 (m, 3H), 7.11 (d, 2H, $J = 8.6$ Hz), 6.78 (d, 2H, $J = 8.6$ Hz), 5.89-5.85 (m, 2H), 5.31-5.29 (m, 4H), 4.68-4.41 (m, 5H), 4.21 (s, 2H), 3.77 (s, 3H), 3.72-3.49 (m, 2H); ^{13}C NMR (CDCl_3 , δ ppm) 169.6, 159.5, 156.6, 147.7, 145.0, 135.1, 133.6, 132.4, 131.7, 131.2, 129.8, 126.1, 124.3, 118.9, 118.0, 117.6, 68.6, 64.1, 55.2, 51.8, 50.4, 47.8; IR (thin film, cm^{-1}) 3345, 3063, 2963, 1791, 1600, 1555, 1528, 1103; MS (ES^+) calculated for $\text{C}_{24}\text{H}_{27}\text{N}_3\text{O}_9\text{S}$, $[\text{M}+\text{H}]^+$ 534.1, found $[\text{M}+\text{H}]^+$ 534.1.

2-(S)-Allyloxycarbonylamino-3-(4-methoxy-benzylamino)-propionic acid allyl ester (16). Thiophenol (0.6 ml, 0.6 mmol) was dissolved in DMF (2 ml) and treated with K_2CO_3 (0.20 g, 1.6 mmol) in water (1 ml), which was then stirred at 0 °C for 10 min.

15 (0.10 g, 0.53 mmol) was dissolved in DMF (1 ml) and added to the thiophenol mixture and stirred overnight at room temperature under a nitrogen atmosphere. Ethyl acetate (10 ml) was added and the mixture washed with water (2 x 10 ml), dried over magnesium sulfate and concentrated *in vacuo* giving a yellow oil. Purification by flash column chromatography on silica gel in DCM:diethyl ether (2:1) removed the yellow fraction. Methanol:DCM (5:95) was then added to give **16** as a light brown oil (0.15 g, 80%). R_f 0.37, DCM:diethyl ether (2:1) (stain ninhydrin, yellow spot); ^1H NMR (CDCl_3 , δ ppm) 7.20 (d, 2H, $J = 8.4$ Hz), 6.85 (d, 2H, $J = 8.7$ Hz), 5.95-5.82 (m, 2H), 5.72 (d, 1H, $J = 6.3$ Hz), 5.34-5.23 (m, 4H), 4.64-4.56 (m, 4H), 4.44-4.41 (m, 1H), 3.80 (s, 2H), 3.79 (s, 3H), 3.72 (dd, 2H, $J = 4.5, 3.3$ Hz). ^{13}C NMR (CDCl_3 , δ ppm) 166.1, 159.7, 155.9, 146.7, 131.2, 128.9, 119.5, 67.9, 55.3, 52.8, 51.2, 48.7. IR (thin film, cm^{-1}) 3311, 3030, 2876, 1720, 1666, 1489; MS (ES^+) calculated for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_5$, $[\text{M}+1]$ 649.2, found $[\text{M}+1]$ 649.2.

2-(S)-Allyloxycarbonylamino-3-[(4-methoxy-benzyl)-[2-(S)-methoxycarbonyl-2-(toluene-4-sulfonylamino)-ethyl]-amino]-propionic acid allyl ester (17).

Aziridine **2a** (0.65 g, 0.28 mmol) and DAP **16** (0.10 g, 0.28 mmol) were dissolved in dry DCM (5 ml) and stirred at room temperature, under a nitrogen atmosphere, for 20 min. Freshly distilled $\text{BF}_3 \cdot \text{OEt}_2$ (0.01 ml, 0.1 mmol) was then added and the mixture was stirred at 40 °C for 24 hr. The mixture was then diluted with DCM (10 ml) and washed with saturated aqueous NaHCO_3 solution (10 ml) and water (10 ml), dried over magnesium sulfate, and then the solvent was removed *in vacuo* giving a brown residue. Purification by preparative TLC in petroleum ether:ethyl acetate (2:1) gave **17** as a clear oil (48 mg, 30%). R_f 0.26, petroleum ether:ethyl acetate (2:1); ^1H NMR (CDCl_3 , δ ppm) 7.74 (d, 2H, $J = 8.2$ Hz), 7.30 (d, 2H, $J = 8.0$ Hz), 7.20 (d, 2H, $J = 5.3$ Hz), 6.65 (d, 2H, $J = 6.3$ Hz), 5.99-5.82 (m, 2H), 5.73 (s, 1H, $J = 17.4$ Hz), 5.50 (d, 1H, $J = 12.9$ Hz), 5.35-5.23 (m, 4H), 4.60 (dd, 4H, $J = 5.6, 5.5$ Hz), 4.44-4.36 (m, 2H), 3.97 (dd, 2H, $J = 4.2, 3.6$ Hz), 3.88 (d, 2H, $J = 3.6$ Hz), 3.80 (s, 3H), 3.73 (d, 2H, $J = 3.6$ Hz), 2.96 (s, 3H), 2.42 (s, 3H); MS (ES^+) calculated for $\text{C}_{29}\text{H}_{37}\text{N}_3\text{O}_9\text{S}$, $[\text{M}+\text{H}]^+$ 604.3, found $[\text{M}+\text{H}]^+$ 604.3.

(2R)-Methyl 2-(((S)-3-methoxy-2-(4-nitrophenylsulfonamido)-3-oxopropyl)(4-methoxybenzyl)amino)-3S-(4-methylphenylsulfonamido) propanoate (18).

18 was synthesised using a similar method to that used to synthesise **8**, except the protected Dap **5a** and aziridine **2a** were used. The crude product was purified using preparatory TLC on silica gel (petroleum ether:ethyl acetate 4:1) to yield **18** as a pale yellow oil (0.08 g, 47%). R_f: 0.29 petroleum ether:ethyl acetate (1:1); ¹H NMR (CDCl₃, δ ppm) 8.33 (d, 2H, *J* = 8.9 Hz), 8.00 (d, 2H, *J* = 8.7 Hz), 7.69 (d, 2H, *J* = 8.0 Hz), 7.28 (d, 2H, *J* = 8.1 Hz), 7.08 (d, 2H, *J* = 8.4 Hz), 6.84 (d, 2H, *J* = 8.4 Hz), 3.98 (t, 1H, *J* = 6.5 Hz), 3.81 (s, 3H), 3.73 (s, 3H), 3.65 (d, 1H, *J* = 13.0 Hz), 3.55 (d, 1H, *J* = 12.9 Hz), 3.50 (s, 3H), 3.46 (m, 1H), 3.23 (m, 1H), 3.09 (m, 2H), 3.00 (m, 1H), 2.42 (s, 3H); ¹³C NMR (CDCl₃, δ ppm) 170.9, 170.7, 159.3, 150.1, 145.5, 143.6, 136.6, 130.4, 129.7, 128.4, 127.0, 124.2, 114.1, 62.7, 55.3, 55.3, 55.2, 54.5, 52.4, 52.1, 41.4, 21.5; IR (thin film, cm⁻¹) 3391, 3078, 2962, 1745, 1732, 1529, 1391, 1249, 1141.

(2R)-Methyl 3-(((S)-1-allyloxy-3-(4-methylphenylsulfonamido)-1-oxopropan-2-yl)(4-methoxybenzyl)amino)-2-(4-nitrophenylsulfonamido) propanoate (19)

19 was synthesised using a similar method to that used to synthesise **18**, except the protected Dap **5a** and aziridine **2b** were used. The crude product was purified using preparatory TLC on silica gel (petroleum ether:ethyl acetate 4:1) to yield **19** as a pale yellow oil 0.07g, 39%). R_f: 0.24 petroleum ether:ethyl acetate (1:1); ¹H NMR (CDCl₃, δ ppm) 8.32 (d, 2H, *J* = 8.8 Hz), 8.00 (d, 2H, *J* = 8.8 Hz), 7.68 (d, 2H, *J* = 8.7 Hz), 7.27 (d, 2H, *J* = 8.6 Hz), 7.11 (d, 2H, *J* = 8.7 Hz), 6.84 (d, 2H, *J* = 8.7 Hz), 5.66 (m, 1H), 5.20 (m, 3H), 4.35 (d, 2H, *J* = 6.0 Hz), 3.97 (t, 1H), 3.81 (s, 3H), 3.72 (s, 3H), 3.66 (d, 1H, *J* = 13.5 Hz), 3.57 (d, 1H, *J* = 13.5 Hz), 3.46 (m, 1H), 3.25 (m, 1H), 3.10-2.98 (m, 3H), 2.41 (s, 3H); ¹³C NMR (CDCl₃, δ ppm) 170.9, 170.0, 159.3, 150.1, 145.5, 143.5, 136.7, 130.6, 130.5, 129.7, 128.5, 127.0, 124.3, 120.0, 114.1, 66.8, 62.8, 55.5, 55.4, 55.3, 54.6, 52.1, 41.5, 21.5; IR (thin film, cm⁻¹) 3376, 3065, 2963, 1751, 1732, 1684, 1524, 1391, 1247.

(L)-Threonine methyl ester hydrochloride.⁸ A 250 ml 3-necked round-bottom flask was equipped with a condenser, a dropping funnel and a rubber septum. The condenser was fitted with a calcium chloride drying tube. The dropping funnel was charged with acetyl chloride (23.0 ml, 0.33 mol). The flask was filled with 75 mls of methanol and cooled to 0 °C in an ice bath under nitrogen. The acetyl chloride is added dropwise over 5 mins before L-threonine (13.58 g, 0.11 mol) was added before heating to reflux temperature. After 2 hours the solvent is removed *in vacuo* to yield a white fluffy solid (18.75 g, 97%) which was used without further purification. ¹H NMR (CDCl₃, δ ppm) 4.12 (d, 1H, *J* = 5.8 Hz), 3.87 (d, 1H, *J* = 5.8 Hz), 3.78 (dd, 1H, *J* = 5.3, 5.2 Hz), 3.67 (s, 3H), 1.21 (d, 3H, *J* = 6.0 Hz). ¹³C NMR (CDCl₃, δ ppm) 169.2, 60.9, 54.9, 52.1, 19.2. **IR** (KBr, cm⁻¹) 3407, 2967, 1745.

N-trityl-(L)-threonine methyl ester was synthesised using a similar method to that used to synthesise **14**, except *(L)-threonine methyl ester hydrochloride* (0.54 g, 3.2 mmol) was used, to yield a white solid (0.98 g, 82%).⁸ R_f: 0.50 petroleum ether:ethyl acetate (2:1). ¹H NMR (CDCl₃, δ ppm) 7.49 (m, 6H), 7.31-7.14 (m, 9H), 3.78 (m, 1H), 3.38 (d, 1H *J* = 3.5 Hz), 3.15 (s, 3H), 1.22 (d, 3H *J* = 6.3 Hz). ¹³C NMR (CDCl₃, δ ppm) 173.7, 145.4, 128.9, 127.9, 126.6, 69.7, 62.5, 53.4, 51.7, 18.9. **IR** (KBr, cm⁻¹) 3481, 3055, 2978, 1732, 1592.

N-Triphenylmethyl-(L)-threonine. *N*-Triphenylmethyl-(L)-threonine was synthesised using a similar method to that used to synthesise *N*-triphenylmethyl-(*S*)-serine (**13**), except L-threonine (1.13 g, 9.5 mmol) was used to yield a white solid (2.02 g, 59%). ¹H NMR (CDCl₃, δ ppm) 7.40 (d, 6H, *J* = 6.0 Hz), 7.28-7.15 (m, 9H), 3.91 (m, 1H), 3.52 (dd, 1H, *J* = 5.9, 5.8 Hz), 1.19 (d, 3H, *J* = 5.6 Hz); ¹³C NMR (CDCl₃, δ ppm) 174.6, 145.2, 128.6, 127.7, 126.6, 70.6, 60.5, 54.8, 18.3; **IR** (KBr, cm⁻¹) 3341, 3082, 2977, 1737.

N-Triphenylmethyl-(L)-threonine allyl ester. *N-Triphenylmethyl-(L)-threonine allyl ester* was synthesised using a similar method to that used to synthesise *N-trityl-(L)-serine methyl ester*, except *N-triphenylmethyl-(L)-threonine* (0.31 g, 0.87 mmol) was used to yield a brown oil (0.31 g, 90%). R_f: 0.60 petroleum ether:ethyl acetate (2:1); ¹H NMR (CDCl₃, δ ppm) 7.49 (m, 6H), 7.28-7.12 (m, 9H), 5.63 (m, 1H), 5.16 (m, 2H), 4.06 (m, 1H), 3.82 (m, 2H), 3.40 (d, 1H *J* = 7.3 Hz), 1.22 (d, 3H *J* = 6.1 Hz); ¹³C NMR (CDCl₃, δ ppm) 173.0, 145.5, 131.6, 129.0, 127.9, 126.7, 118.8, 70.8, 69.8, 62.5, 53.5, 19.0; IR (thin film, cm⁻¹) 3446, 3058, 2931, 1732, 1674.

(2S,3R)-Methyl-1-(trityl)-aziridine-2-carboxylic acid methyl ester (20a). **20a** was synthesised using a similar method to that used to synthesise **1a**, except *N-trityl-(L)-threonine methyl ester* (2.06 g, 5.5 mmol) was used, to yield a cloudy oil (1.79 g, 91%). R_f: 0.82 petroleum ether:ethyl acetate (2:1); ¹H NMR (CDCl₃, δ ppm) 7.53 (m, 6H), 7.28-7.13 (m, 9H), 3.67 (s, 3H), 1.90 (dd, 1H, *J* = 3.8, 3.7 Hz), 1.66 (m, 1H), 1.36 (d, 3H, *J* = 6.2 Hz); ¹³C NMR (CDCl₃, δ ppm) 170.8, 144.2, 129.5, 127.7, 127.0, 75.1, 51.9, 36.1, 35.0, 13.4; IR (thin film, cm⁻¹) 3069, 2947, 1739.

(2S,3R)-Methyl-1-trityl-aziridine-2-carboxylic acid allyl ester (20b). **20b** was synthesised using a similar method to that used to synthesise **1b**, except *N-triphenylmethyl-(L)-threonine allyl ester* (2.07 g, 5.16 mmol) was used to yield **20b** as a yellow oil (1.72 g, 87%). R_f: 0.90 petroleum ether:ethyl acetate (2:1); ¹H NMR (CDCl₃, δ ppm) 7.45 (m, 6H), 7.31-7.19 (m, 9H), 5.88 (m, 1H), 5.24 (m, 2H), 4.59 (m, 2H), 1.84 (d, 1H *J* = 6.5 Hz), 1.55 (m, 1H), 1.27 (d, 3H *J* = 5.5 Hz); ¹³C NMR (CDCl₃) δ ppm; 170.0, 143.9, 132.2, 129.4, 128.3, 126.6, 118.5, 82.0, 65.4, 36.0, 35.0, 13.4; IR (thin film, cm⁻¹) 3080, 2975, 1742, 1641.

(2S,3R)-Methyl-1-(p-tosyl)-aziridine-2-carboxylic acid methyl ester (21a). **21a** was synthesised using a similar method to that used to synthesise **2a**, except **20a** (2.07 g, 5.8 mmol) was used to yield a clear oil (1.26 g, 81%). R_f: 0.47 petroleum ether:ethyl acetate (2:1); ¹H NMR (CDCl₃, δ ppm) 7.85 (d, 2H, *J* = 8.4 Hz), 7.35 (d, 2H, *J* = 8.3 Hz), 3.73 (s, 3H), 3.39 (d, 1H, *J* = 7.5 Hz), 3.10 (m, 1H), 2.44 (s, 3H), 1.32 (d, 3H, *J* = 5.6 Hz); ¹³C NMR (CDCl₃, δ ppm) 166.2, 145.0, 136.6, 129.8, 128.0, 53.0, 41.4, 40.1, 21.6, 12.4; IR (thin film, cm⁻¹) 3072, 2979, 1741, 1214 .

(2*S*,3*R*)-Methyl-1-(*p*-nosyl)-aziridine-2-carboxylic acid methyl ester (**21b**). **21b** was synthesised using a similar method to that used to synthesise **2b**, except **20a** (2.07 g, 5.8 mmol) was used to yield a yellow oil (1.39 g, 80%). R_f: 0.51 petroleum ether:ethyl acetate (2:1); ¹H NMR (CDCl₃, δ ppm) 8.35 (d, 2H, *J* = 8.8 Hz), 8.14 (d, 2H, *J* = 8.8 Hz), 3.68 (s, 3H), 3.44 (d, 1H, *J* = 7.5 Hz), 3.18 (m, 1H), 1.21 (d, 3H, *J* = 5.7 Hz); ¹³C NMR (CDCl₃, δ ppm) 165.6, 150.8, 145.4, 129.2, 124.4, 52.8, 42.2, 40.7, 12.4; IR (thin film, cm⁻¹) 3080, 2967, 1747, 1540, 1379, 1276.

(2*S*,3*R*)-Methyl-1-(*p*-nitrobenzyloxycarbony)-aziridine-2-carboxylic acid methyl ester (**21c**). **21c** was synthesised using a similar method to that used to synthesise **2c**, except **20a** (2.07 g, 5.8 mmol) was used to yield a yellow oil (1.33 g, 78%). R_f: 0.45 petroleum ether:ethyl acetate (2:1); ¹H NMR (CDCl₃, δ ppm) 8.08 (d, 2H, *J* = 8.8 Hz), 7.44 (d, 2H, *J* = 8.8 Hz), 5.12 (d, 2H, *J* = 3.1 Hz), 3.67 (s, 3H), 3.18 (d, 1H, *J* = 6.7 Hz), 2.78 (m, 1H), 1.27 (d, 3H, *J* = 5.6 Hz); ¹³C NMR (CDCl₃, δ ppm) 171.4, 161.2, 147.6, 143.9, 129.2, 123.4, 66.8, 53.6, 39.8, 39.0, 12.6; IR (thin film, cm⁻¹) 3065, 2981, 1744, 1680, 1528, 1397, 1212.

(2*S*,3*R*)-Methyl-1-(*p*-tosyl)-aziridine-2-carboxylic acid allyl ester (**22a**). **22a** was synthesised using a similar method to that used to synthesise **3a**, except **20b** (2.07 g, 5.4 mmol) was used to yield a clear oil (1.34 g, 84%). R_f: 0.47 petroleum ether:ethyl acetate (2:1); ¹H NMR (CDCl₃, δ ppm) 7.85 (d, 2H, *J* = 8.8 Hz), 7.35 (d, 2H, *J* = 8.8 Hz), 5.88 (m, 1H), 5.22 (m, 2H), 4.65 (d, 2H, *J* = 6.0 Hz), 3.39 (d, 1H, *J* = 6.6 Hz), 3.10 (m, 1H), 2.44 (s, 3H), 1.32 (d, 3H, *J* = 5.8 Hz); ¹³C NMR (CDCl₃, δ ppm) 166.2, 145.0, 136.6, 131.1, 129.8, 128.0, 119.0, 66.5, 41.4, 40.1, 21.6, 12.4; IR (thin film, cm⁻¹) 3090, 2992, 1740, 1621, 1220.

(2*S*,3*R*)-Methyl-1-(*p*-nosyl)-aziridine-2-carboxylic acid allyl ester (**22b**). **22b** was synthesised using a similar method to that used to synthesise **3b**, except **20b** (2.07 g, 5.4 mmol) was used to yield a yellow oil (1.35g, 77%). R_f: 0.54 petroleum ether:ethyl acetate (2:1); ¹H NMR (CDCl₃, δ ppm) 8.35 (d, 2H, *J* = 9.0 Hz), 8.14 (d, 2H, *J* = 8.9 Hz), 5.86 (m 1H), 5.26 (m, 2H), 4.57 (d, 2H, *J* = 5.8 Hz), 3.48 (d, 1H, *J* = 7.5 Hz), 3.20 (m, 1H), 1.29 (d, 3H *J* = 5.7 Hz); ¹³C NMR (CDCl₃, δ ppm) 164.8, 150.8, 143.5, 130.9, 129.2, 124.4, 119.5, 66.5, 42.0, 40.7, 12.3; IR (thin film, cm⁻¹) 3077, 2954, 1742, 1538, 1371, 1242.

(2*S*,3*R*)-Methyl-1-(*p*-nitrobenzyloxycarbonyl)-aziridine-2-carboxylic acid allyl ester (**22c**). **22c** was synthesised using a similar method to that used to synthesise **3c**, except **20b** (2.07 g, 5.4 mmol) was used to yield a yellow oil (1.29 g, 75%). R_f: 0.42 petroleum ether:ethyl acetate (2:1); ¹H NMR (CDCl₃, δ ppm) 8.25 (d, 2H, *J* = 8.8 Hz), 7.55 (d, 2H, *J* = 8.8 Hz), 5.90 (m, 1H), 5.38-5.19 (m, 4H), 4.70 (d, 2H, *J* = 5.8 Hz), 3.23 (d, 1H, *J* = 6.7 Hz), 2.88 (m, 1H), 1.39 (d, 3H, *J* = 5.6 Hz); ¹³C NMR (CDCl₃, δ ppm) 166.6, 161.1, 147.8, 142.4, 131.3, 128.5, 123.8, 119.2, 66.9, 66.2, 39.9, 39.1, 12.7; IR (thin film, cm⁻¹) 3068, 2982, 1741, 1681, 1640, 1209.

DAPs **23a**, **24a**, **23b**, **24b**, **25a-c** and **26** were prepared by ring-opening of 3-methyl aziridines with *p*-methoxybenzylamine using the general procedure used to prepare DAPs **4a-c** and **6c**.

(2*S*,3*R*)-Methyl 3-(4-methoxybenzylamino)-2-(4-methylphenylsulfonamido) butanoate (**23a**). Cloudy oil (0.08 g, 41%); R_f: 0.18 petroleum ether:ethyl acetate (1:1); [α]_D²⁰ = +16.55° (*c* 1.0 in CHCl₃); ¹H NMR (CDCl₃, δ ppm) 7.71 (d, 2H, *J* = 8.1 Hz), 7.28 (d, 2H, *J* = 8.0 Hz), 7.13 (d, 2H, *J* = 8.4 Hz), 6.82 (d, 2H, *J* = 8.4 Hz), 3.81 (d, 1H, *J* = 3.6 Hz), 3.80 (s, 3H), 3.68 (d, 1H, *J* = 12.8 Hz), 3.55 (d, 1H, *J* = 12.8 Hz), 3.45 (s, 3H), 3.09 (m, 1H), 2.41 (s, 3H), 1.13 (d, 3H, *J* = 6.2 Hz); ¹³C NMR (CDCl₃, δ ppm) 171.1, 158.7, 143.5, 136.7, 131.8, 129.5, 129.3, 127.2, 113.7, 60.4, 55.2, 53.9, 52.3, 50.3, 21.5, 17.6; IR (thin film, cm⁻¹) 3411, 3077, 2977, 1733, 1213, 1126; HRMS (ES⁺) calculated for C₂₀H₂₇N₂O₅S, [M+H]⁺ 407.1635, found [M+H]⁺ 407.1628.

(2*S*,3*R*)-Methyl 3-(4-methoxybenzylamino)-2-(4-nitrophenylsulfonamido) butanoate (**23b**). Pale yellow oil (0.09 g, 42%); R_f: 0.45 petroleum ether:ethyl acetate (1:1); [α]_D²⁰ = +7.10° (*c* 1.0 in CHCl₃); ¹H NMR (CDCl₃, δ ppm) 8.32 (d, 2H, *J* = 8.7 Hz), 8.03 (d, 2H, *J* = 8.7 Hz), 7.13 (d, 2H, *J* = 8.4 Hz), 6.83 (d, 2H, *J* = 8.5 Hz), 3.88 (d, 1H, *J* = 3.2 Hz), 3.78 (s, 3H), 3.65 (d, 2H, *J* = 12.6 Hz), 3.49 (d, 1H, *J* = 12.7 Hz), 3.47 (s, 3H), 3.18 (m, 1H), 1.17 (d, 2H, *J* = 5.6 Hz); ¹³C NMR (CDCl₃, δ ppm) 170.8, 158.9, 149.9, 145.9, 131.0, 129.4, 128.4, 124.6, 113.8, 60.2, 55.3, 53.8, 52.6, 50.6, 18.0; IR (thin film, cm⁻¹) 3352, 3066, 2967, 1741, 1521, 1386, 1191; HRMS (ES⁺) calculated for C₁₉H₂₄N₃O₇S, [M+H]⁺ 438.1329, found [M+H]⁺ 438.1330.

(2*R*,3*S*)-Methyl 2-(4-methoxybenzylamino)-3-(4-methylphenylsulfonamido) butanoate (**24a**). R_f : 0.29 petroleum ether:ethyl acetate (1:1); ^1H NMR (CDCl_3 , δ ppm) 7.64 (d, 2H, $J = 8.4$ Hz), 7.20 (d, 2H, $J = 8.4$ Hz), 7.10 (d, 2H, $J = 8.6$ Hz), 6.78 (d, 2H, $J = 8.6$ Hz), 3.73 (s, 3H), 3.65-3.50 (dd, 2H, $J = 12.6, 12.6$ Hz), 3.56 (s, 3H), 3.50 (d, 1H, $J = 12.6$ Hz), 3.43 (m, 1H), 3.01 (d, 1H, $J = 5.1$ Hz), 2.33 (s, 3H), 1.02 (d, 3H, $J = 6.5$ Hz). ^{13}C NMR (CDCl_3 , δ ppm) 172.8, 158.9, 143.3, 137.5, 130.7, 129.6, 129.6, 127.2, 113.8, 64.2, 55.3, 52.4, 52.0, 51.5, 21.5, 17.6; IR (thin film, cm^{-1}) 3365, 3089, 2982, 1738, 1194, 1133.

(2*S*,3*R*)-Allyl 3-(4-methoxybenzylamino)-2-(4-methylphenylsulfonamido) butanoate (**25a**). Pale yellow oil (0.09 g, 42%); R_f : 0.2 petroleum ether:ethyl acetate (1:1); $[\alpha]_D^{20} = +21.83^\circ$ (c 1.0 in CHCl_3); ^1H NMR (CDCl_3 , δ ppm) 7.72 (d, 2H, $J = 8.3$ Hz), 7.27 (d, 2H, $J = 8.3$ Hz), 7.15 (d, 2H, $J = 8.4$ Hz), 6.83 (d, 2H, $J = 8.4$ Hz), 5.66 (m, 1H), 5.16 (m, 2H), 4.38-4.25 (dd, 2H, $J = 6.0, 6.0$ Hz), 3.82 (d, 1H, $J = 3.6$ Hz), 3.78 (s, 3H), 3.71 (d, 1H, $J = 13.2$ Hz), 3.54 (d, 1H, $J = 13.2$ Hz), 3.12 (m, 1H), 2.40 (s, 3H), 1.15 (d, 3H, $J = 6.5$ Hz); ^{13}C NMR (CDCl_3 , δ ppm) 170.3, 158.7, 143.5, 136.7, 131.7, 131.1, 129.6, 129.3, 127.2, 119.0, 113.7, 66.1, 60.1, 55.2, 54.0, 50.3, 21.5, 17.5; IR (thin film, cm^{-1}) 3346, 3081, 2962, 1744, 1612, 1201, 1152; HRMS (ES+) calculated for $\text{C}_{22}\text{H}_{29}\text{N}_2\text{O}_5\text{S}$, $[\text{M}+\text{H}]^+$ 433.1792, found $[\text{M}+\text{H}]^+$ 433.1796.

(2*S*,3*R*)-Allyl 3-(4-methoxybenzylamino)-2-(4-nitrophenylsulfonamido) butanoate (**25b**). Pale yellow oil (0.1 g, 43%); R_f : 0.41 petroleum ether:ethyl acetate (1:1); $[\alpha]_D^{20} = +12.37^\circ$ (c 1.0 in CHCl_3); ^1H NMR (CDCl_3 , δ ppm) 8.31 (d, 2H, $J = 8.8$ Hz), 8.01 (d, 2H, $J = 8.8$ Hz), 7.12 (d, 2H, $J = 8.5$ Hz), 6.84 (d, 2H, $J = 8.5$ Hz), 5.63 (m, 1H), 5.18 (m, 2H), 4.42 (dd, 1H, $J = 12.8, 6.1$ Hz), 4.30 (dd, 1H, $J = 12.7, 6.1$ Hz), 3.88 (d, 1H, $J = 4.6$ Hz), 3.78 (s, 3H), 3.68 (d, 1H, $J = 12.8$ Hz), 3.51 (d, 1H, $J = 12.8$ Hz), 3.21 (m, 1H), 1.19 (d, 3H, $J = 6.3$ Hz); ^{13}C NMR (CDCl_3 , δ ppm) 170.1, 158.8, 149.9, 145.9, 131.6, 130.0, 129.2, 128.4, 124.6, 119.5, 113.8, 66.4, 60.3, 55.2, 53.9, 50.8, 18.2; IR (thin film, cm^{-1}) 3397, 3069, 2981, 1738, 1612, 1557, 1379, 1176; HRMS (ES+) calculated for $\text{C}_{21}\text{H}_{26}\text{N}_3\text{O}_7\text{S}$, $[\text{M}+\text{H}]^+$ 464.1486, found $[\text{M}+\text{H}]^+$ 464.1504.

(2*S*,3*R*)-Allyl 3-(4-methoxybenzylamino)-2-((4-nitrobenzyloxy)carbonylamino) butanoate (**25c**). Pale yellow oil (0.09 g, 39%); R_f: 0.50 petroleum ether:ethyl acetate (1:1); [α]_D²⁰ = +29.62° (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, δ ppm) 8.19 (d, 2H *J* = 8.8 Hz), 7.51 (d, 2H *J* = 8.8 Hz), 7.17 (d, 2H *J* = 8.9 Hz), 6.85 (d, 2H *J* = 8.8 Hz), 6.08 (s (br), 1H), 5.90 (m, 1H), 5.36-5.25 (m, 2H), 4.80 (s, 2H), 4.64 (d, 2H, *J* = 6.0 Hz), 4.27 (pseudo t, 2H, *J* = 4.3 Hz), 3.79 (s, 3H), 3.24 (d, 1H *J* = 7.2 Hz), 2.78 (m, 1H), 1.29 (d, 3H *J* = 5.6 Hz); ¹³C NMR (CDCl₃, δ ppm) 167.8, 163.1, 159.0, 148.5, 147.5, 131.4, 129.8, 129.2, 126.9, 123.6, 119.1, 114.0, 66.2, 63.8, 55.3, 44.4, 40.5, 39.4, 13.0; IR (thin film, cm⁻¹) 3380, 3071, 2980, 1742, 1666, 1206; HRMS: (ES⁺) calculated for C₂₃H₂₈N₃O₇, calculated [M+H]⁺ 458.1943, found [M+H]⁺ 458.1922.

(2*R*,3*S*)-Allyl 2-(4-methoxybenzylamino)-3-(4-nitrophenylsulfonamido) butanoate (**26b**). R_f: 0.52 petroleum ether:ethyl acetate (1:1). ¹H NMR (CDCl₃, δ ppm) 8.28 (d, 2H, *J* = 8.8 Hz), 7.96 (d, 2H, *J* = 8.7 Hz), 7.07 (d, 2H, *J* = 8.4 Hz), 6.80 (d, 2H, *J* = 8.4 Hz), 5.63 (m, 1H), 5.18 (m, 2H), 4.26 (dd, 2H, *J* = 6.2, 6.1 Hz), 3.80 (s, 3H), 3.72 (d, 1H, *J* = 12.9 Hz), 3.58 (d, 1H, *J* = 12.9 Hz), 3.28 (m, 1H), 2.98 (d, 1H, *J* = 7.4 Hz), 1.07 (d, 2H, *J* = 5.8 Hz). ¹³C NMR (CDCl₃, δ ppm) 172.8, 158.8, 149.9, 147.6, 131.5, 130.9, 129.0, 128.5, 124.1, 119.2, 113.8, 66.5, 63.8, 55.2, 52.9, 51.1, 18.1. IR (thin film, cm⁻¹) 3368, 3068, 2979, 1739, 1622, 1552, 1378, 1165.

Acknowledgements

We are grateful to Strand I of the Irish Government's National Development Plan Technological Sector Research Program for funding (Grant PP07/TA07) for K O'B and the Higher Education Authority's Programme for Research in Third-Level Institutions IV for funding for K ó P and K O'B.

References and Notes

1. Liskamp, R.; Rijkers, D.; Bakker, S. Bioactive Macrocyclic Peptides and Peptide Mimics. In *Modern Supramolecular Chemistry: Strategies for Macrocyclic Synthesis*; Diedrich, F; Stang, P.; Tykwinski, R., Eds.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, **2008**.
2. (a) Taylor, C.; De Silva, S-T. *J. Org. Chem.* **2011**, *76*, 5703-5711. (b) Taylor, C.; Wang, W. *Tetrahedron* **2007**, *63*, 9033-9047. (c) Boschin, G.;

- D'Agostina, A.; Arnoldi, A. *Food Chemistry* **2002**, *78*, 325-331. (d) Friedman, M. *J. Agric. Food Chem.* **1999**, *47*, 1295-1319.
3. (a) Arnison, P. G.; Bibb, M. J.; Bierbaum, G.; Bowers, A. A.; Bugni, T. S.; Bulaj, G.; Camarero, J. A.; Campopiano, D. J.; Challis, G. L.; Clardy, J.; Cotter, P. D.; Craik, D. J.; Dawson, M.; Dittmann, E.; Donadio, S.; Dorrestein, P. C.; Entian, K-D.; Fischbach, M. A.; Garavelli, J. S.; Göransson, U.; Gruber, C. W.; Haft, D. H.; Hemscheidt, T. K.; Hertweck, C.; Hill, C.; Horswill, A. R.; Jaspars, M.; Kelly, W. L.; Klinman, J. P.; Kuipers, O. P.; Link, A. J.; Liu, W.; Marahiel, M. A.; Mitchell, D. A.; Moll, G. N.; Moore, B. S.; Müller, R.; Nair, S. K.; Nes, I. F.; Norris, G. E.; Olivera, B. M.; Onaka, H.; Patchett, M. L.; Piel, J.; Reaney, M. J. T.; Rebuffat, S.; Ross, R. P.; Sahl, H-G.; Schmidt, E. W.; Selsted, M. E.; Severinov, K.; Shen, B.; Sivonen, K.; Smith, L.; Stein, T.; Süßmuth, R. D.; Tagg, J. R.; Tang, G-L.; Truman, A. W.; Vederas, J. C.; Walsh, C. T.; Walton, J. D.; Wenzel, S. C.; Willey, J. M.; Van der Donk, W. *Nat. Prod. Rep.* **2013**, *30*, 108-160. (b) Knerr, P. J.; Van der Donk, W. A. *Annu. Rev. Biochem.* **2012**, *81*, 479-505.
 4. Tabor, A. *Org. Biomol. Chem.* **2011**, *9*, 7606-7628.
 5. (a) Ross, A. C.; McKinnie, S. M. K.; Vederas, J. C. *J. Am. Chem. Soc.* **2012**, *134*, 2008-2011. (c) Liu, H.; Pattabiraman, V. R.; Vederas, J. C. *Org. Lett.* **2009**, *11*, 5574-5577. (c) Liu, H.; Pattabiraman, V.; Vederas, J. *Org. Lett.*, **2007**, *9*, 4211-4214.
 6. O'Brien, K.; ó Proinsias, K.; Kelleher, F. *Tetrahedron Lett.* **2013**, *54*, 2395-2397.
 7. (a) Pérez, M.; Pleixats, R. *Tetrahedron* **1995**, *51*, 8355-8362. (b) Paulus, T.; Riemer, C.; Beck-Sickinger, A.G.; Henle, T.; Klostermeyer, H. *Eur. Food Res. Technol.* **2006**, *222*, 242-249. (c) Kim, B. M.; So, S. M. *Tetrahedron Lett.* **1999**, *40*, 7687-7690.
 8. Willems, J. G. H.; Hersmis, M. C.; de Gelder, R.; Smits, J. M. M.; Hammink, J. B.; Dommerholt, F. J.; Thijs, L.; Zwanenburg, B. *J. Chem. Soc. Perkin Trans. 1*, **1997**, 963-967.
 9. O'Brien, K.; Kelleher, F. *Tetrahedron Lett.* **2013**, *54*, 6627-6630.
 10. Kelleher, F.; ó Proinsias, K. *Tetrahedron Lett.* **2007**, *48*, 4879-4882.

11. Nakajima, K.; Oda, H.; Okawa, K. *Bull. Chem. Soc. Jpn.* **1983**, *56*, 520-522.

ACCEPTED MANUSCRIPT

Studies on the synthesis of orthogonally protected azalanthionines, and of routes towards β -methyl azalanthionines, by ring-opening of N-activated aziridine-2-carboxylates

Keith O'Brien, Keith ó Proinsias and Fintan Kelleher*

Molecular Design and Synthesis Group, Centre of Applied Science for Health, Institute of Technology Tallaght, Dublin 24, Ireland.

Supporting Information

All isolated products were purified using column chromatography with silica gel (Aldrich, 70-230 mesh, 60 Å) in the indicated solvent systems. Melting points were determined with Stuart scientific SMP1 & Mettler FP62 melting point apparatus. Analytical thin layer chromatography (TLC) was performed on pre-coated plates (Merck Kieselgel 60 F₂₅₄) and visualised with UV light (254 nm), iodine vapour or aqueous potassium permanganate solution. Infrared spectra were recorded as KBr disks or a thin film between sodium chloride plates, on Avatar 320 and Nicolet impact 410 FT-IR spectrophotometers, run on EZ Omnic E.S.P 5.2a and 3.1a software packages, respectively. Polarimetry was carried out using an Optical Activity AA-55 series polarimeter at ambient temperature with a 2 dm, 1 ml cell. ¹H NMR and ¹³C NMR spectra were measured on a JOEL JNM-LA300 FT-NMR or a Bruker Avance III 500 MHz FT-NMR with TopSpin 2.16 Software and 5mm PATXI 1H/13-C/15N Z-GRD probe, in CDCl₃ as solvent. Chemical shift values are reported relative to tetramethylsilane. Mass Spectrometry was carried out at the Centre for Synthesis and Chemical Biology in University College Dublin using Quattro *micro*TM LC-MS/MS and Liquid chromatography time-of-flight (LCT) mass spectrometers. Exact Mass Spectrometry analyses were carried out at the Department of Chemistry, NUI Maynooth, Co. Kildare, Ireland.

N-Triyl-(S)-serine methyl ester. To a suspension of (*S*)-serine methyl ester hydrochloride (0.50 g, 3.2 mmol) in DCM (7 ml) at 0 °C, under a nitrogen atmosphere, was added dropwise triethylamine (1.0 ml, 7.1 mmol), followed by a solution of triphenylmethyl chloride (0.91 g, 3.2 mmol) in DCM (2 ml). After stirring at 0 °C for 12 h the white precipitate was filtered and the filtrate was concentrated *in vacuo* to yield a white solid which was dissolved in ethyl acetate (10 ml), washed with 1 M aqueous NaHCO₃ solution (10 ml), 10% aqueous citric acid

solution (10 ml) and water (10 ml). The organic layer was dried over anhydrous magnesium sulfate and concentrated *in vacuo* giving a white solid. Purification by flash column chromatography on silica gel in petroleum ether:ethyl acetate (4:1), gave *N*-trityl-(*S*)-serine methyl ester as a white solid (0.99 g, 86%). R_f : 0.42, petroleum ether:ethyl acetate (2:1); M.pt. 98-100 °C; $[\alpha]_D^{20} = +3.65^\circ$ (c 1.0 in CHCl_3) (Lit. Value $[\alpha]_D^{20} = +3.60^\circ$ (c 1 in CHCl_3))¹; $^1\text{H NMR}$ (CDCl_3 , δ ppm) 7.47 (m, 6H), 7.21 (m, 9H), 3.73 (dd, 1H, $J = 4.2$ and 4.1 Hz), 3.56 (m, 2H), 3.26 (s, 3H); $^{13}\text{C NMR}$ (CDCl_3 , δ ppm) 173.9, 145.5, 128.6, 127.8, 126.5, 70.8, 64.8, 57.7, 51.8; IR (KBr, cm^{-1}) 3354, 3060, 2947, 1731.

The enantiomeric *N*-trityl-(*R*)-serine methyl ester was also prepared in a similar manner from (*R*)-serine methyl ester hydrochloride.

1-Trityl-aziridine-2S-carboxylic acid methyl ester (1a). Triethylamine (1.68 ml, 12.1 mmol) was added dropwise over 10 min to a stirred solution of *N*-trityl-(*S*)-serine methyl ester (2.0 g, 5.5 mmol) in THF (50 ml) at 0 °C, followed by the dropwise addition of methanesulfonyl chloride (0.47 ml, 60.0 mmol) and the solution was stirred at 0 °C for 30 mins giving the mesylate intermediate and was subsequently heated at reflux temperature for 48 h. After completion of the reaction, solvent was removed under reduced pressure. The resulting residue was dissolved in EtOAc (60 ml) and washed with 10% aqueous citric acid solution (3 x 20 ml), H_2O (2 x 20 ml), saturated aqueous Na_2CO_3 solution (3 x 20 ml), H_2O (2 x 20 ml) and brine (20 ml). The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated *in vacuo*. Purification by flash column chromatography on silica gel in petroleum ether:ethyl acetate (4:1), gave **1a** as a cloudy oil (1.8 g, 95%). R_f : 0.84 petroleum ether:ethyl acetate (2:1); $[\alpha]_D^{20} = -94^\circ$ (c 1.0 in CHCl_3) (Lit. Value $[\alpha]_D^{20} = -94.22^\circ$ (c 1 in CHCl_3))²; $^1\text{H NMR}$ (CDCl_3 , δ ppm) 7.47 (dd, $J = 7.1, 7.2$ Hz), 7.34-7.30 (m, 6H), 7.28-7.23 (m, 3H), 3.66 (s, 3H), 1.88 (dd, 2H, $J = 4.1, 3.9$ Hz), 1.42 (dd, 1H, $J = 4.1, 4.1$ Hz); $^{13}\text{C NMR}$ (CDCl_3 , δ ppm) 170.5, 146.7, 129.3, 127.9, 126.9, 74.5, 65.7, 31.7, 28.7; IR (thin film, cm^{-1}) 3058, 2925, 1744.

The enantiomeric **R-1a** was also prepared in a similar manner from *N*-trityl-(*R*)-serine methyl ester.

I-(p-Tosyl)-aziridine-2S-carboxylic acid methyl ester (2a). Trifluoroacetic acid (10 ml) was added dropwise over 10 min to a solution of **1a** (2.0 g, 5.8 mmol) in dichloromethane (10 ml) and methanol (10 ml) at 0 °C and stirred for 30 min at 0 °C. Volatiles were removed by azeotropic removal with Et₂O (3 x 10 ml). The residue was partitioned between Et₂O (50 ml) and H₂O (50 ml) and the ether layer was extracted with water (3 x 10 ml). The combined aqueous layers were basified to pH 9 with solid NaHCO₃ at 0 °C. Ethyl acetate (100 ml) was added to the aqueous solution followed by *p*-toluenesulfonyl chloride (1.11 g, 5.8 mmol) at 0 °C. The resulting immiscible layers were allowed to warm to room temperature and stirred vigorously for 24 h. After completion of the reaction, the two layers were separated and the aqueous layer was extracted with EtOAc (3 x 20 ml). The combined organic layers were washed with brine (3 x 50 ml), dried over anhydrous magnesium sulfate, filtered and concentrated *in vacuo*. The crude product was purified by flash column chromatography on silica gel in petroleum ether:ethyl acetate (4:1) to yield **2a** as a clear oil (1.36 g, 92%). $[\alpha]_D^{20} = -54.81^\circ$ (*c* 1.0 in CHCl₃) (Lit. Value $[\alpha]_D = -55.2^\circ$ (*c* 1.17 in CHCl₃))³; ¹H NMR (CDCl₃, δ ppm) 7.78 (d, 2H, *J* = 8.4 Hz), 7.30 (d, 2H, *J* = 8.4 Hz), 3.73 (s, 3H), 3.33 (m, 1H), 2.76 (d, 1H, *J* = 7.2 Hz), 2.59 (d, 1H, *J* = 4.2 Hz), 2.44 (s, 3H); ¹³C NMR (CDCl₃, δ ppm) 167.3, 145.4, 133.7, 129.8, 128.1, 52.8, 35.6, 31.9, 21.8; IR (thin film, cm⁻¹) 3079, 2983, 1741, 1220.

The enantiomeric **R-2a** was also prepared in a similar manner from **R-1a**.

I-(p-Nosyl)-aziridine-2S-carboxylic acid methyl ester (2b). **2b** was synthesised using a similar method to that used to synthesise **2a**, except 4-nitrobenzylsulfonyl chloride was used. The crude product was purified by flash column chromatography on silica gel in petroleum ether:ethyl acetate (4:1) to yield **2b** as a yellow oil (1.29 g, 85%). R_f: 0.48 petroleum ether:ethyl acetate (2:1); $[\alpha]_D^{20} = -61.77^\circ$ (*c* 1.0 in CHCl₃); ¹H NMR (CDCl₃, δ ppm) 8.36 (d, 2H, *J* = 9.0 Hz), 8.13 (d, 2H, *J* = 9.0 Hz), 3.69 (s, 3H), 3.38 (m, 1H), 2.83 (d, 1H *J* = 7.1 Hz), 2.60 (d, 1H *J* = 4.2 Hz); ¹³C NMR (CDCl₃, δ ppm) 166.6, 154.1, 142.9, 129.5, 124.5, 53.1, 36.1, 32.5; IR (thin film, cm⁻¹) 3084, 2918, 1750, 1546, 1369, 1312, 1297.

The enantiomeric **R-2b** was also prepared in a similar manner from **R-1a**.

l-(*p*-Nitrobenzyloxycarbonyl)-aziridine-2*S*-carboxylic acid methyl ester (**2c**). **2c** was synthesised using a similar method to that used to synthesise **2a**, except 4-nitrobenzyl chloroformate was used. The crude product was purified using flash column chromatography on silica gel in petroleum ether:ethyl acetate (4:1) to yield **2c** as a yellow oil (1.38 g, 82%). R_f: 0.48 petroleum ether:ethyl acetate (2:1); [α]_D²⁰ = -30.26° (c 1.0 in CHCl₃) (Lit. Value [α]_D = -30.26° (c 1 in CHCl₃))²; ¹H NMR (CDCl₃, δ ppm) 8.15 (d, 2H, *J* = 8.8 Hz), 7.46 (d, 2H, *J* = 8.6 Hz), 5.19 (d, 2H, *J* = 5.2 Hz), 3.67 (s, 3H), 3.09 (dd, 1H, *J* = 4.2 Hz and *J* = 4.2 Hz), 2.57 (dd, 1H, *J* = 1.3, 1.3 Hz), 2.45 (dd, 1H, *J* = 1.2, 1.2 Hz); ¹³C NMR (CDCl₃, δ ppm) 169.0, 160.2, 147.9, 142.6, 128.5, 123.7, 66.9, 53.1, 35.0, 31.4; IR (thin film, cm⁻¹) 3071, 2936, 1742, 1690, 1516, 1351, 1303, 1281.

The enantiomeric **R-2c** was also prepared in a similar manner from **R-1a**.

l-Trityl-aziridine-2*S*-carboxylic acid allyl ester (**1b**). **1b** was synthesised using a similar method to that used to synthesise **1a**, except **13** (2.0 g, 5.16 mmol) was used instead of *N*-trityl-(*S*)-serine methyl ester. Purification by flash column chromatography on silica gel in petroleum ether:ethyl acetate (4:1), gave **1b** as a white solid (1.75 g, 92%). R_f: 0.85 petroleum ether:ethyl acetate (2:1); [α]_D²⁰ = -97.12° (c 1.0 in CHCl₃) (Lit. Value [α]_D²⁰ (c 1 in CHCl₃) = -97.01°)²; ¹H NMR (CDCl₃, δ ppm) 7.46 (dd, *J* = 7.2, 7.1 Hz), 7.31-7.27 (m, 6H), 7.26-7.23 (m, 3H), 5.84-5.72 (m, 1H), 5.37 (dd, 1H, *J* = 7.1, 6.3 Hz), 5.24-5.19 (m, 1H), 4.70-4.66 (m, 2H), 1.90 (dd, 2H, *J* = 4.1, 3.9 Hz), 1.42 (dd, 1H, *J* = 4.1, 4.1 Hz); ¹³C NMR (CDCl₃, δ ppm) 171.0, 145.8, 129.6, 128.7, 126.8, 131.7, 118.5, 74.3, 65.7, 31.7, 28.7; IR (thin film, cm⁻¹) 3091, 2966, 1749, 1672.

The enantiomeric **R-1b** was also prepared in a similar manner from **R-7**.

l-(*p*-Tosyl)-aziridine-2*S*-carboxylic acid allyl ester (**3a**). **3a** was synthesised using a similar method to that used to synthesise **2a**, except **1b** and 4-toluenesulfonyl chloride (1.04 g, 5.4 mmol) were used. The crude product was purified using flash column chromatography on silica gel in petroleum ether:ethyl acetate (4:1) to yield **3a** as a clear oil (1.28 g, 83%). R_f: 0.5 petroleum ether:ethyl acetate (2:1); [α]_D²⁰ = -58.37° (c 1.0 in CHCl₃); ¹H NMR (CDCl₃, δ ppm) 7.86 (d, 2H, *J* = 8.4 Hz), 7.37 (d, 2H, *J* = 8.4 Hz), 5.93-5.84 (m, 1H), 5.26-5.14 (m, 2H), 4.60 (d, 2H, *J* = 7.2 and 6.2 Hz), 3.36 (m, 1H), 2.76 (d, 1H, *J* = 7.2 Hz), 2.58 (d, 1H, *J* = 4.1 Hz), 2.45 (s, 3H); ¹³C NMR (CDCl₃, δ ppm) 166.5, 145.0, 139.9, 130.6, 129.7, 127.7, 119.0, 66.4, 35.8, 32.0, 21.5; IR (thin film, cm⁻¹) 3077, 2969, 1734, 1638, 1158.

The enantiomeric **R-3a** was also prepared in a similar manner from **R-1b**.

l-(*p*-Nosyl)-aziridine-2*S*-carboxylic acid allyl ester (**3b**). **3b** was synthesised using a similar method to that used to synthesise **3a**, except 4-nitrobenzenesulfonyl chloride (1.27 g, 5.4 mmol) was used. The crude product was purified using flash column chromatography on silica gel in petroleum ether:ethyl acetate (4:1) to yield **174** as a yellow oil (1.37 g, 80%). R_f : 0.53 petroleum ether:ethyl acetate (2:1); $[\alpha]_D^{20} = -64.28^\circ$ (c 1.0 in CHCl_3); $^1\text{H NMR}$ (CDCl_3 , δ ppm) 8.41 (d, 2H $J = 9.0$ Hz), 8.22 (d, 2H $J = 9.0$ Hz), 5.90 (m, 1H), 5.28 (m, 2H), 4.64 (d, 2H $J = 5.8$ Hz), 3.47 (dd, 1H $J = 4.2, 4.2$ Hz), 2.91 (d, 1H $J = 7.1$ Hz), 2.68 (d, 1H $J = 4.2$ Hz); $^{13}\text{C NMR}$ (CDCl_3 , δ ppm) 165.8, 150.9, 142.9, 130.8, 129.5, 124.5, 119.5, 66.8, 36.3, 32.5; IR (thin film, cm^{-1}) 3067, 2987, 1740, 1642, 1202.

The enantiomeric **R-3b** was also prepared in a similar manner from **R-1b**.

l-(*p*-Nitrobenzyloxycarbonyl)-aziridine-2*S*-carboxylic acid allyl ester (**3c**). **3c** was synthesised using a similar method to that used to synthesise **3a**, except 4-nitrobenzyl chloroformate (1.16 g, 5.4 mmol) was used. The crude product was purified using flash column chromatography on silica gel in petroleum ether:ethyl acetate (4:1) to yield **3c** as a yellow oil (0.95 g, 82%). R_f : 0.49 petroleum ether:ethyl acetate (2:1). $[\alpha]_D^{20} = -23.01^\circ$ (c 1.0 in CHCl_3) (Lit. Value $[\alpha]_D = -23.76^\circ$ (c 1.0 in CHCl_3))²; $^1\text{H NMR}$ (CDCl_3 , δ ppm) 8.22 (d, 2H, $J = 8.8$ Hz), 7.53 (d, 2H, $J = 8.8$ Hz), 5.89 (m, 1H), 5.37-5.27 (m, 4H), 4.62 (d, 2H, $J = 5.9$ Hz), 3.22 (dd, 1H, $J = 3.2, 3.2$ Hz), 2.65 (dd, 1H, $J = 1.2, 1.2$ Hz) 2.57 (dd, 1H, $J = 1.2, 1.2$ Hz); $^{13}\text{C NMR}$ (CDCl_3 , δ ppm) 167.8, 160.2, 147.8, 142.4, 131.6, 128.4, 123.4, 119.1, 66.8, 66.4, 34.9, 31.4; IR (thin film, cm^{-1}) 3062, 2993, 1738, 1695, 1642, 1202.

The enantiomeric **R-3c** was also prepared in a similar manner from **R-1b**.

l-(Allyloxycarbonyl)-aziridine-2*S*-carboxylic acid allyl ester (**7**). **7** was synthesised using a similar method to that used to synthesise **3a**, except allyl chloroformate (1.7 mls, 5.4 mmol) was used. The crude product was purified using flash column chromatography on silica gel in petroleum ether:ethyl acetate (4:1) to yield **7** as a brown oil (0.39 g, 34%). R_f : 0.56 petroleum ether:ethyl acetate (2:1); $[\alpha]_D^{20} = -63.51^\circ$ (c 1.0 in CHCl_3); $^1\text{H NMR}$ (CDCl_3 , δ ppm) 5.90 (m, 4H), 5.31 (m, 4H), 4.74-4.61 (m, 4H), 3.13 (dd, 1H, $J = 3.1$ Hz and $J = 3.1$ Hz), 2.61 (dd, 1H, $J = 1.3, 1.3$ Hz), 2.50 (dd, 1H, $J = 1.4, 1.3$ Hz); $^{13}\text{C NMR}$ (CDCl_3 , δ ppm) 167.1, 156.9, 131.7, 131.2, 118.8, 118.5, 67.57, 67.51, 31.3, 29.7; IR (thin film, cm^{-1}) 2957, 1732, 1662, 1617.

N-(4-Methoxybenzyl)-2-nitrobenzenesulfonamide. 4-Methoxybenzylamine (0.34 g, 2.5 mmol) was dissolved in DCM (3 ml) and triethylamine (0.4 ml, 2.5 mmol). The mixture was cooled in an ice bath and *o*-nitrobenzenesulfonyl chloride (0.5 g, 2.3 mmol) was added portionwise over a period of 20 min. The mixture was then stirred at room temperature for 12 h. 1 M HCl (30 ml) was added and the solution extracted with DCM (2 x 30 ml). The combined organic layers were washed with brine (30 ml), dried over magnesium sulfate, and the solvent was removed *in vacuo* giving a brown oil. Recrystallisation from hexane:ethyl acetate (1:1) gave *N*-(*p*-Methoxybenzyl)-2-nitrobenzenesulfonamide as white crystals (5.8 g, 78%). R_f 0.53, petroleum ether:ethyl acetate (1:2); M.pt. 120-121 °C; ^1H NMR (CDCl_3 , δ ppm) 8.01 (d, 1H, $J = 9.0$ Hz), 7.83 (d, 1H, $J = 9.3$ Hz), 7.69- 7.58 (m, 2H), 7.12 (d, 2H, $J = 8.7$ Hz), 6.75 (d, 2H, $J = 8.7$ Hz), 5.63 (d, 1H, $J = 12.0$ Hz), 4.24 (d, 2H, $J = 6.3$ Hz), 3.75 (s, 3H); ^{13}C NMR (CDCl_3 , δ ppm) 159.4, 148.0, 135.0, 133.3, 132.6, 131.1, 129.3, 127.6, 125.2, 114.0, 55.3, 47.4; IR (KBr, cm^{-1}) 3308, 3021, 1540, 1364, 1158. MS (ES^+) calculated for $\text{C}_{14}\text{H}_{14}\text{N}_2\text{O}_5\text{S}$, $[2\text{M}+\text{Na}]^+$ 667.2, found $[2\text{M}+\text{Na}]^+$ 667.2.

References

1. Harada, H.; Morie, T.; Suzuki, T.; Yoshida, T.; Kato, S. *Tetrahedron* **1998**, *54*, 10671-10676.
2. Liu, H.; Pattabiraman, V.; Vederas, J. *Org. Lett.*, **2007**, *9*, 4211-4214.
3. Baldwin, J.; Farthing, C.; Russell, A.; Schofield, C. J.; Spivey, A. C. *Tetrahedron Lett.*, **1996**, *37*, 3754-3761.